Podcasts about landstrom

In kurzer Abfolge hat Nicko Cruises beziehungsweise deren Muttergesellschaft Mystic Ocean die Vasco da Gama seit 2021 jährlich in die Werft geschickt. Im April 2025 war sie wieder bei Lisnave in Portugal und hat dort vor allem technische Upgrades gekommen, die das schon etwas ältere Kreuzfahrtschiff für aktuelle und künftige Umwelt- und Klimaschutz-Vorschriften fit macht. Cruisetricks.de hat die Vasco da Gama in der Werft besucht. In dieser Podcast-Episode sprechen wir über die Modernisierung und Renovierung der Vasco da Gama. Dabei lassen wir auch Nicko-Cruises‘ Geschäftsführer Guide Laukamp zu Wort kommen, der die vielen Neuerungen und Modernisierungsmaßnahmen au der Vasco da Gama erklärt. Landstrom hat das Schiff beispielsweise bekommen – eine wichtige Voraussetzung in zwar noch wenigen, aber immer mehr werdenden Kreuzfahrthäfen der Welt, um dort überhaupt noch anlegen zu dürfen. Für EU- und wahrscheinlich bald auch weltweite IMO-Vorschriften wichtig ist die Fähigkeit von Kreuzfahrtschiffen, mit alternativen, sprich: klimafreundlicheren Treibstoffen fahren zu können. Auch hierfür hat die Vasco da Gama ein wesentliches Upgrade bekommen, über das wir in dieser Podcast-Episode sprechen. Neben technischen Neuerungen hat Nicko Cruises aber auch die bereits bei früheren Werftaufenthalten begonnene Renovierung der öffentlichen Bereiche fortgesetzt, mit teils neuen Möbeln und Teppichen, aufgearbeiteten Holzböden, dem Ersatz der Badewannen in den Kabinen auf Deck 5 durch moderne Duschkabinen beispielsweise. Für mehr Komfort dürfte auch die komplett neue Hydraulik und Steuerung der Stabilisatoren und vor allem der komplette Austausch der Klimaanlagen-Technik sorgen. Letztere hatte zuletzt große Probleme bereitet. Und auch schnelle Starlink-Internet kann die Vasco da Gama jetzt bieten. In der Aftershow sprechen wir über neue Emissionskontroll-Zonen, die von der International Maritime Organization IMO beschlossen wurden beziehungsweise geplant werden und bleiben damit beim Thema Umwelt- und Klimaschutz. Wir sprechen darüber, wo es solche Schutzzonen bislang bereits gibt und wie die neuen ECAs in der kanadischen Arktis und entlang der Küste Norwegens ab 2027 sowie große Bereiche entlang der Küsten im Nordatlantik wahrscheinlich ab 2028 zum Schutz der Meere, der Atmosphäre und der Gesundheit der Menschen entlang der Schifffahrtsrouten beitragen. Die After-Show, ebenso wie die werbefreie Version des Podcasts, ist ein besonderes Goodie [exklusiv für unsere Unterstützer via Steady](https://steadyhq.com/de/cruisetricks-podcast/about), das wir in einem eigenen, kleinen Podcast bereitstellen. Bei Steady finden Sie als Abonnent eine [genaue Anleitung](https://get.steadyhq.help/hc/de/articles/360002251118), wie Sie diesen Podcast abonnieren können. Werbefrei hören den Podcast all diejenigen von Ihnen, die uns mit einem Steady-Abonnement monatlich unterstützen. Den Podcast und die After-Show gibt es deshalb für Steady-Abonnenten an einem Stück komplett und ohne Werbeunterbrechungen über den personalisierten RSS-Podcast-Feed bei Steady – siehe oben.

Host Dominik Hoffmann und Vollbluttouristikerin Sainey Sawaneh stechen mit den Kreuzfahrtmatrosen Tobias und Dominik, die seit 2016 schon 30 Kreuzfahrten unternommen haben, in See. Die Themen: Heimathafen ist Stuttgart; Hochzeitsreise als erste Kreuzfahrt; Himmel & Meer Suite; Große Vielfalt – auch für Laktoseintoleranz; Kreuzfahrt-Kompetenz als solamento Reiseberater; Drei Kreuzfahrtreisen pro Jahr; Mein Schiff Jungfernfahrt-Inszenierung; Taufzeremonie mit Champagnerflasche; Umwelt mit grünem Methanol im Fokus; Landstrom und Liegezeit; Sommer im Nordland, Winter auf den Kanaren; Lieblingshafen Die Welt ist schön, schau sie dir an. Finde Deinen persönlichen Reiseberater auf https://solamento.com/ Schreib uns deine Fragen und Anmerkungen an: podcast@solamento.de

Bei Familie Block hat es wieder eine Razzia gegeben; ein Hamburger Politiker ist Opfer eines perfiden Angriffs geworden; Schüler müssen jetzt im Unterricht ihr Gesicht zeigen; in Freibädern wird Sonnencreme verschenkt; Containerschiffe bekommen grünen Saft - unter anderem das und noch einen Aufreger gibt es in unserem Wochenrückblick.

Was war heute in Hamburg los? Maiken Nielsen und Ole Wackermann werfen im wöchentlichen Wechsel zum Tagesende einen Blick auf die News und das aktuelle Stadtgeschehen. Das sind die Nachrichten heute mit Elke Spanner, am Montag, 13. Mai 2024: +++ Aufstieg perfekt! St. Pauli ist zurück in der Bundesliga +++ Der FC St. Pauli ist zurück in der Fußball-Bundesliga! Am Sonntag gelang dem Team von Trainer Fabian Hürzeler mit dem 3:1 (1:0) gegen den VfL Osnabrück der letzte Schritt zum vorzeitigen Aufstieg. Schon vor und während der Partie herrschte am Millerntor Partystimmung.

In dieser Folge spricht AIDAradio Moderator Thorsten Jost mit Marco Torkler und Tim Wolfram von Carnival Maritime über Landstrom. Welche Vorreiter-Rolle hat AIDA Cruises bisher übernommen, welche Fäden laufen bei den beiden zusammen und wie sieht es in der Zukunft mit Landstrom aus. All diese Fragen beantworten die beiden in dieser Folge.

Andrew Landstrom, MD, PhD talks living out passion, discussing the uncertainties of genetic testing in the clinic, and the exciting future of diagnostics in medicine. 

Actor Ben Butters discusses his role as Chase, the German shepherd police dog in “Paw Patrol Live!,” on stage at the Fox Theatre September 8 through 10. Plus, artist Bob Landstrom takes the spotlight in our series, “Speaking of Art.”See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Für die 3. Live-Folge vom Caravan Salon hat sich Nele mal das EcoFlow-Sortiment genauer angeschaut und von Brand Manager Udo Reetz erklären lassen. Angefangen bei den kleinen tragbaren Powerstations über leistungsstarke "Mini-Kraftwerke" für Wohnmobile und Wohnwagen bis hin zu den passenden Solarpanels. Die portable Heizungs-/Klimaanlage Wave 2 und die Kühlbox Glacier mit Eiswürfelbereiter sind super interessant. Du hörst viele spannende Infos, wenn du möglichst unabhängig vom Landstrom sein willst. Falls auch du tolle Neuheiten auf der Messe entdeckt hast oder uns etwas anderes mitteilen willst, schickt gerne eine Nachricht an podcast@camperstyle.de oder per Whatsapp (https://wa.me/message/V3JDATZ3SUNHC1).

08/16/23: Horace City Councilwoman Stephanie Landstrom will keep her seat after defeating challenger Arlin Fisher in a recall election on Tuesday, August 15th. She joins Joel on "News and Views" to talk about the recall efforts.  Read the full article at KFGO.com. See omnystudio.com/listener for privacy information.

Join us as we sit down with the remarkable Ann Landstrom, an award-winning photographer who defied the odds to pursue her passion. From escaping an abusive marriage to empowering women through her lens, Ann's journey is both inspiring and uplifting.Discover how she found her calling, worked with big names in the industry, and created projects that redefine beauty and self-expression. Tune in for heartfelt conversations, life-changing moments, and a glimpse into the power of photography to transform lives.Get ready to be inspired, motivated, and captivated by Ann's incredible story of resilience and triumph.

Stephanie Landstrom, Horace City Council, is on Afternoons Live to discuss her vote to sunset tax abatement in her community and what she believes is behind the recall effort against her.See omnystudio.com/listener for privacy information.

This is a testimonial by Ann Landstrom of the Dr. Finance® Masterclass Club by Dr. Anthony M. Criniti IV (aka “Dr. Finance®”). For more information about the club, please visit https://drfinance.info/masterclass-clubDr. Anthony M. Criniti IV (aka “Dr. Finance®”) is the world's leading financial scientist and survivalist.  A fifth generation native of Philadelphia, Dr. Criniti is a former finance professor at several universities, a former financial planner, an active investor in diverse marketplaces, an explorer, an international keynote speaker, and has traveled around the world studying various aspects of finance.  He is an award winning author of three #1 international best-selling finance books: The Necessity of Finance (2013), The Most Important Lessons in Economics and Finance (2014), and The Survival of the Richest (2016).  Dr. Criniti is also the host of the highly successful Dr. Finance® Live Podcast as well as one of the top hosts on Clubhouse.  Dr. Criniti has started a grassroots movement that is changing the way that we think about economics and finance.   For more information about Doctor Finance, please visit https://DrFinance.Info. Disclaimer: This video is for informational purposes only. It is presented with the understanding that the author(s) and the publisher(s) are not engaged in providing financial, legal, or other professional services. If financial, legal, or any other form of advice is needed, please consult a financial advisor, an attorney, or another professional advice-giving entity. Also, the opinions and views expressed by anyone on the video do not necessarily represent the opinions and views of Dr. Finance® or its affiliates. Copyright © 2023 to Present by Dr. Anthony M. Criniti IV - All Rights Reserved.

In diesem Podcast widmen wir uns dem Thema Nachhaltigkeit. In unserer aktuellen Folge spricht AIDA Radio Prime Time Show Moderator Thorsten Jost mit Marko Torkler und Tim Wolfram. Sie arbeiten beide im Bereich der Technical Operations bei Carnival Maritime. Es geht um das Thema Landstrom und die Vorreiterrolle die AIDA dabei spielt.

Endlich haben wir es geschafft, ein paar Tage mit der A-Rosa Sena zu fahren. Das Flusskreuzfahrtschiff ist schon seit Juni 2022 in Dienst, jetzt hatten wir endlich die Gelegenheit – beziehungsweise die Zeit im Terminkalender – für eine kurze Reise mit dem innovativen Flusskreuzfahrtschiff. Die A-Rosa Sena ist gleich in vieler Hinsicht besonders: Sie ist das größte Flusskreuzfahrtschiff Europas und das wahrscheinlich umweltfreundlichste der Welt. Außerdem zielt ihr Konzept auch auf eine für Flusskreuzfahrten ungewöhnliche Zielgruppe: Familien. Dazu gibt es an Bord einen Kids Club, spezielle Familien-Kabinen und am Sonnendeck sogar einen eigenen Pool für Kinder. Wir haben uns das Schiff genau angesehen und sprechen in dieser Podcast-Episode ausführlich über die Besonderheiten der A-Rosa Sena, mit einem besonderen Schwerpunkt auch auf den Umwelt-Features: Akkus, Landstrom, Peak-Shaving-Technik, SCR-Katalysatoren und noch einiges mehr. After-Show als Bonus und Extra-Podcast für unsere Steady-Abonnenten: In der „After Show“ zu dieser Podcast-Episode sprechen wir über den plötzlichen Abgang des CEO der Costa Group, Michael Thamm, mögliche Gründe und Folgen. Außerdem geht es um einen Führungswechsel auf der Position des CEO und President von Celebrity Cruises. Die After Show ist ein besonderes Goodie [exklusiv für unsere Unterstützer via Steady](https://steadyhq.com/de/cruisetricks-podcast/about), das wir in einem eigenen, kleinen Podcast bereitstellen. Bei Steady finden Sie als Abonnent eine [genaue Anleitung](https://get.steadyhq.help/hc/de/articles/360002251118), wie Sie diesen Podcast abonnieren können.

In the latest episode of the Empowerography Podcast, my guest is Ann Landstrom. With over 20 years in the photography industry, I have perfected my craft and passion to photograph people.  I am proud that I am an award-winning master photographer. I have trained with The Playboy Magazine photographers and I am on the support staff of the biggest online photography education SBE by Sue Bryce and The Portrait Masters. I would love to show YOU how amazing YOU are through my camera. With my expertise in posing and lighting for people of all ages and body types, together we will make some beautiful photographs of you. The experience will empower you and change how you look at yourself. I know how to see and show you your true essence, that you perhaps forgot or maybe ever seen in yourself. There is nothing like not being photogenic you just need the right photographer that knows how to light, pose and coach you to show your inner light and make you shine and show you that YOU are SOULGENIC. In this episode we discuss photography, art, humble beginnings, negative self-talk, mentorship, Lisa Nicholls and branding. Website - https://www.annphotography.com                 https://www.brandingceo.com IG - http://www.instagram.com/annphotography1 FB - https://www.facebook.com/annphotography1 LinkedIn - https://www.linkedin.com/annlandstrom FREE GIFT - Ebook 3 Simple Steps on how to Brand Like a CEO - https://www.brandingceo.com/free   "When I started, again it was before we had digital, it was learning how to do film" - 00:03:43 "You gotta find your niche and your passion and go and get yourself a mentor" - 00:24:27 "I think trusting and believing in yourself" - 00:35:26   THE WORLD needs to hear your message and your story. Don't deny the world of that gift within you that the universe has gave to you. Someone out there needs to hear your story because it will support them in feeling hope, inspired and even transformed. Want to discover how I help my clients get out of their own way, show up and confidently share their message? I would like to invite you to join me Join me in my FREE MASTERCLASS Start Your Own Podcast: Idea to Implementation on Wednesday April 5th at 1:00 pm EST Register Here - https://subscribepage.io/UhL8QL

In the latest episode of the Empowerography Podcast, my guest is Ann Landstrom. With over 20 years in the photography industry, I have perfected my craft and passion to photograph people.  I am proud that I am an award-winning master photographer. I have trained with The Playboy Magazine photographers and I am on the support staff of the biggest online photography education SBE by Sue Bryce and The Portrait Masters. I would love to show YOU how amazing YOU are through my camera. With my expertise in posing and lighting for people of all ages and body types, together we will make some beautiful photographs of you. The experience will empower you and change how you look at yourself. I know how to see and show you your true essence, that you perhaps forgot or maybe ever seen in yourself. There is nothing like not being photogenic you just need the right photographer that knows how to light, pose and coach you to show your inner light and make you shine and show you that YOU are SOULGENIC. In this episode we discuss photography, art, humble beginnings, negative self-talk, mentorship, Lisa Nicholls and branding. Website - https://www.annphotography.com                 https://www.brandingceo.com IG - http://www.instagram.com/annphotography1 FB - https://www.facebook.com/annphotography1 LinkedIn - https://www.linkedin.com/annlandstrom FREE GIFT - Ebook 3 Simple Steps on how to Brand Like a CEO - https://www.brandingceo.com/free   "When I started, again it was before we had digital, it was learning how to do film" - 00:03:43 "You gotta find your niche and your passion and go and get yourself a mentor" - 00:24:27 "I think trusting and believing in yourself" - 00:35:26   THE WORLD needs to hear your message and your story. Don't deny the world of that gift within you that the universe has gave to you. Someone out there needs to hear your story because it will support them in feeling hope, inspired and even transformed. Want to discover how I help my clients get out of their own way, show up and confidently share their message? I would like to invite you to join me Join me in my FREE MASTERCLASS Start Your Own Podcast: Idea to Implementation on Wednesday April 5th at 1:00 pm EST Register Here - https://subscribepage.io/UhL8QL

This week the guys are back to close out their coverage of the KBF events down in Polk county Florida. We dive back into the hot fishing that produced so many giant fish all week. We get into some of the challenges anglers face mentally such as wether or not to move to other spots or put your head down and grind on what you have as well as the mental game watching so many other guys throw up massive limits of fish. We talk flipping, punching, and everyone's favorite frogging for big ol largemouth. We also dive into what it's like making it to the Ten event and competing against the top anglers in the sport as well as one of the guys not knowing what all bonuses awaited him when he made it there. Be sure and follow the guys Ryan @rnye15 Glenn @coldblooded_hoosier Jump into the KBF events here https://www.kayakbassfishing.com/ And be sure and sign up for the annual PaddleNFin Dale Hollow event brought to you by East Port Marina here. https://tourneyx.com/leaderboard/standings/paddlenfin-open-at-dale-hollow-2023 Sign Up For Dale Hollow Event- https://tourneyx.com/leaderboard/standings/paddlenfin-open-at-dale-hollow-2023 Dale Hollow Lodging- www.eastport.info Waypoint TV- https://waypointtv.com Podcast & Website- www.paddlenfin.com YouTube- https://www.youtube.com/paddlenfin Email- paddlenfin@gmail.com Social Media- @paddlenfin Yak Gadget- www.yakgadget.com Pelican Professional- www.pelican.com Rocktown paddlesports - rocktownadventures.com JigMasters Jigs- https://jigmasters.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Muss man etwas über Lithium-Batterien wissen? Wir finden: Ja! Angefangen bei den Unterschieden zur AGM-Batterie, über die Auswahl, die Einstellungen des Ladegeräts über die Frage, warum Thomas keinen Landstrom anschließt bis zur Frage, ob eine Powerstation nicht die bessere Wahl wäre. Spannung zeigt den Ladezustand (in Ruhe, d.h. ohne Ent-/Ladung): - 13,4V und mehr: Akku voll - 13-13,3V 30-95 % Ladezustand - 13V etwa 30 % Ladezustand erreicht - 12V weniger als 5 % Ladezustand des Lithiumakku - 11,5V in dem Dreh schaltet das BMS bei den meisten Akkus ab. Quelle: https://www.amumot-shop.de/ratgeber/lithium-batterien-lifepo4-richtig-laden ## Sicherheitshinweis Diese Episode gibt nur unsere Erfahrung wieder. Arbeiten an der Stromversorgung sollten nur von entsprechend Kundigen ausgeführt werden. ## Links - Blog-Artikel https://camperstyle.de/die-richtige-bordbatterie-fuer-dein-wohnmobil/ und Podcast mit Andre Bonsch von Amumot https://camperstyle.de/podcast-elektrik-fur-anfanger-batterien-im-camper/ - Batterie-Computer Episode https://www.abgefahrn-podcast.de/batteriecomputer/ - Rettungskarte https://www.promobil.de/tipp/gratis-download-rettungskarte-fuer-wohnmobil-im-fall-der-faelle/ - LFP-Bausatz Hersteller https://lifepo.de/ - Batterie-Selbstbau YT https://g8n.eu/ oder https://www.akkudoktor.net/youtube/ - XiaoXiang-App https://www.lithiumbatterypcb.com/smart-bms-software-download/ für Apple auch https://web.e77code.com/xiaoxiang-bms/

Nicht erst seit der aktuellen Energiekrise wird im Hamburger Hafen an Alternativen zu fossilen Brennstoffen gearbeitet. Hier ist das Zentrum der Wärmewende in der Stadt - vom Landstrom über die große Hoffnung Wasserstoff und das LNG. Und vor wenigen Tagen ist die Bohrmaschine für den neuen Fernwärmetunnel unter der Elbe angekommen. Alles zu Energie im Hafen, zu den aktuellen Projekten, zum Beispiel auch zur Wärmegewinnung aus Industrieabwärme und aus Abwasser, gibt es diese Woche im Hamburger Hafenkonzert.  Moderation: Anja Grigoleit und Dietrich Lehmann

Schweröl als Schiffstreibstoff steht zu Recht in der Dauerkritik. Insbesondere klimaneutrale Alternativen sind in Reichweite, aber im Wesentlichen noch nicht einsatzfähig. Wir werfen in dieser Podcast-Episode einen Blick auf die Möglichkeiten und Schwierigkeiten für die Kreuzfahrt, möglichst bald umweltfreundlich und klimaneutral zu werden. Wir sprechen zu diesem Thema über Energie-Effizienz und Treibstoffverbrauch, Lebensdauer der Schiffe, den aktuellen Stand mit Marinediesel oder Schweröl plus Scrubber und Katalysator sowie die komplizierten Bedingungen für den Einsatz neuer Techniken. Vor allem aber beschäftigen wir uns mit alternativen Kraftstoffen und Energieträgern, mit denen die Kreuzfahrt – und die Schifffahrt insgesamt – in absehbarer Zeit deutlich sauberer, wenn nicht sogar schadstofffrei und klimaneutral werden kann. Angesprochen werdend dabei die Möglichkeiten, Chancen und der Entwicklungsstand von LNG, synthetischem Gas und Bio-Gas, Bio-Diesel, Methanol, Wasserstoff, Ammoniak, Brennstoffzellen, Akkus und Landstrom. Hinweis und Bitte: Cruisetricks.de hat seinen Youtube-Kanal https://www.youtube.com/c/CruisetricksDe neu belebt und wird künftig kürzere Highlight-Videos zu jedem Schiff produzieren, auf dem wir fahren. Damit Youtube uns an den Einnahmen aus der im Video eingeblendeten Werbung beteiligt und nicht alles selbst einsackt, benötigen wir unter anderem mindestens 1.000 Abonnenten des Kanals ... Unterstützen Sie uns und abonnieren Sie jetzt gleich den CruisetricksDe-Youtubekanal: https://www.youtube.com/c/CruisetricksDe (kostenlos). After-Show als Bonus und Extra-Podcast für unsere Steady-Abonnenten: In der „After Show“ zu dieser Podcast-Episode bleiben wir bei einem ähnlichen Thema wie in der Haupt-Episode und sprechen wir über Energie-Effizienz: die Möglichkeiten und Entwicklungen für Kreuzfahrtschiffe, mit weniger Energiebedarf auszukommen. Dazu gehört beispielsweise die Technik, den Reibungswiderstand des Rumpfs mit kleinen Luftblasen zu reduzieren, aber auch viele andere Wege, etwa Windkraft, niedrigere Fahrtgeschwindigkeiten oder effizienterer Hotelbetrieb von Beleuchtung bis Klimaanlage. Die After Show ist ein besonderes Goodie [exklusiv für unsere Unterstützer via Steady](https://steadyhq.com/de/cruisetricks-podcast/about), das wir in einem eigenen, kleinen Podcast bereitstellen. Bei Steady finden Sie als Abonnent eine [genaue Anleitung](https://get.steadyhq.help/hc/de/articles/360002251118), wie Sie diesen Podcast abonnieren können.

We're back with a new episode of the HKB 22 Podcast! What a week! Listen in to get the latest on what's happening in the Hoosier State. Plus, hear from Glenn about his record-setting month! For more information about HKB, visit HoosierKayakBassin.com

Wofür brauchen wir überhaupt alles Strom in einem Freizeitfahrzeug? Und was hat es mit diesem "Landstrom" und der 12V-Versorgung auf sich? Wir wollen uns in dieser ersten Folge zum Thema Strom ein paar grundlegenden Fragen und Themen zum Strom im Campervan, Wohnwagen oder auch Wohnmobil widmen. Es wird über die Unterschiede zwischen der 230V und 12V Versorgung gehen und was man beim Anschluss an das Auto oder eine "Steckdose" beachten muss. Wir streifen auch das Thema Batterie, aber natürlich nur ganz grundlegend.

Molly + Jodi talk all things pottery with Hester Prouty of Prouty Pottery in Rapid City SD.  From clay made right here in South Dakota to purchasing a studio in the Landstrom's building in Rapid City, we dig into Hester's story and the why beneath her work.https://proutypottery.com/https://www.ginnysonline.com/

Dr. Reshma Sundar and Dr. Marene Landström from the Department of Medical Biosciences at Umeå University in Sweden discuss their experience publishing the research paper, “Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGFβ stimulation in cancer”, with Oncotarget in 2017. DOI - https://doi.org/10.18632/oncotarget.20097 Correspondence to - Marene Landström - Marene.Landstrom@medbio.umu.se Keywords - signal transduction, tumor biology, Snail1, sumoylation, prostate cancer About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Wieder haben wir einen Gast im Podcast, denn das heutige Thema können wir einfach nicht alleine besprechen: Es geht um die Elektrik im Wohnmobilaufbau. Unser Fachmann Flo erklärt uns, was der Fehlerstromschutzschalter (FI) macht, wie man den Camper richtig an den Landstrom hängt und ob man bedenkenlos am 12 Volt Bordnetz werkeln kann. Wir wollten von ihm noch wissen, welchen Wechselrichter man braucht, um Rapunzel die Haare zu föhnen und einen Thermomix zu betreiben. Florian ist da der geeignete Gesprächspartner, denn er hat nicht nur einen Meistertitel in diesem Fach, sondern ist auch für die Sicherheit in einem großen Unternehmen im Bereich Elektrotechnik zuständig. Außerdem versteht er unsere Sprache, denn er ist ebenfalls, zusammen mit seiner Frau Eva, begeisterter Camper und fährt ein schnuckeliges Wohnmobil. Hier hat er bereits schon selbst viel gebastelt und geschraubt, folgen könnt Ihr Flo und Eva mit ihrem Wiesl auf Instagram unter @bayernwieslHier ein paar Links zu besprochenen Produkten im Podcast:25 Meter CEE Kabel 2,5 quadratKabelverbindungen mit Stromdieb oder Scotch Lock Wo Ihr uns sonst noch findet: SteboDie2Mays auf YoutubeDie2Mays auf InstagramDie2Mays auf Facebook NikolajVan3Life auf YoutubeVan3Life auf Instagram

Today's guests: Ann Landstrom Ann is an award-winning master photographer with over 20 years in the photography industry. She has photographed public figures and influencers and has been featured in San Diego magazines, numerous podcasts, and The Huffington Post. Ann specializes in Branding, Boudoir, and Fine Art Portraits, her passion, and drive are to bring out the best version of each of her clients to elevate their business and also their self-esteem. To show them their inner shine and essence they might have forgotten about or never seen in themselves before through her transformational lens." On this episode: Stacey is joined by professional photographer and entrepreneur Ann Landstrom for a conversation on the early struggles of entrepreneurism, positive affirmations, and rescuing yourself. Key Takeaways: -Success isn't fast. Invest the time. Be patient. -Are you running your business like it's a hobby? -Avoid getting trapped by "How?". Tweetable Quotes: "I had to change my mindset when I came here from Sweden. Coaches and mentors played a big part in helping me get where I am." -Ann Landstrom "So often business owners get trapped in analysis paralysis and never get around to doing it... taking the necessary action. " -Stacey O'Byrne "I realized I had to rescue myself." Ann Landstrom "We have to be very clear on what your blind spots are, and it's very difficult to do that ourselves. Business owners need help finding out what they don't know." -Stacey O'Byrne Ann Landstrom: https://www.annphotography.com https://www.instagram.com/annphotography1 Resources: Instagram: @pivotpointadvantage Schedule a 15 minute call with Stacey: http://pivotpointadvantage.com/talktostacey If you're ready to take yourself and your business to the next level and are interested in a coaching program that will get you there check out: http://pivotpointadvantage.com/iwantsuccess Join an interactive environment to help you build the success you've always wanted with other like-minded, success-driven entrepreneurs, business owners, and sales professionals: https://facebook.com/groups/sellwithoutselling

The new executive director of Simpson's Center for Academic Resources, Corey Landstrom, talks about what the office offers all students to help them get the most of their academic career at the college. CAR isn't simply for students struggling in classes; it can help those students who excel with resources to get even more out of their work.

It's time for a break down! Let's talk craft and see what makes this serial fiction episode work. Links: Read on Kindle Vella: https://www.amazon.com/kindle-vella/story/B098WJVJXB Reader's Companion Episode: https://anchor.fm/readersserialfictionshow/episodes/Americas-Most-Dangerous-Ghosts-by-Risse-Landstrom-e16ejro Christine's website: christinedaiglebooks.com JP's website: jprindfleischix.com Find out more about Christine's co-authored serial fiction: lpstylesbooks.com We are sponsored by The Three Story Method Podcast Network. You can find out more about Three Story Method here: threestorymethod.com Sound mastering by James Parenti: jamesparentimusic.com Our theme music is Voxel Revolution by Kevin McAllen: https://incompetech.filmmusic.io/song/7017-voxel-revolution License: https://filmmusic.io/standard-license Contact: serialfictionshow.com/contact Our transition music is by: patrickdearteaga.com

Ghost horror. Loner with a heart of gold Kira can see dead people. When her bad boy best friend convinces her to stay at a haunted hotel with him, the terrifying night becomes an internet sensation. Camera in hand, they hit the road for America's most haunted locales. Poltergeists, cursed items, timeslips, and more test their reflexes and sanity as Kira learns how to help spirits find the light. But as their fame grows, a ghost from Kira's past stalks them, determined to drag Kira into the darkness forever. Links: Read on Kindle Vella: https://www.amazon.com/kindle-vella/story/B098WJVJXB Christine's website: christinedaiglebooks.com JP's website: jprindfleischix.com Find out more about Christine's co-authored serial fiction: lpstylesbooks.com We are sponsored by The Three Story Method Podcast Network. You can find out more about Three Story Method here: threestorymethod.com Sound mastering and narration by James Parenti: jamesparentimusic.com Our theme music is Voxel Revolution by Kevin McAllen: https://incompetech.filmmusic.io/song/7017-voxel-revolution License: https://filmmusic.io/standard-license Contact: serialfictionshow.com/contact Our transition music is by: patrickdearteaga.com

Willkommen zum neuen Cruisify.de Podcast. Hier dreht sich alles um Kreuzfahrten. In dieser Folge bespreche ich kurz und bündig die wichtigsten Themen der vergangenen Woche, spreche über Neuigkeiten in der Kreuzfahrtbranche und was für einen Kreuzfahrt-Fan wichtig ist. Leinen los! Die Themen der Woche: Warnemünde: AIDAsol testet Landstromanlage und bleibt bis 01. Mai dort MSC Cruises: Kooperation mit Saudi-Arabien, drei neue Häfen AIDA Cruises: Buchungstart der Griechenland-Kreuzfahrt erfolgreich angelaufen AIDA Cruises inkludiert weiterhin den PCR-Test im Reisepreis Costa Kreuzfahrten: Vier Schiffe ins Mittelmeer und Absage der Nordeuropa-Kreuzfahrten Unterstütze uns mit deiner Buchung: Direkt zu AIDA Cruises→ Vielen Dank, das du dir diese Episode angehört hast. Mehr Kreuzfahrt-News unter cruisify.de --- Send in a voice message: https://anchor.fm/cruisify-de/message

Stories are a great way to get inspiration & hope. They can help you gain insight into how adoption works and you can learn how other people navigate the journey. I love adoption stories because each one is unique and offers a different perspective. The infant adoption story in this episode is told by Brittney […]

Sebastian ist 23 Jahre alt und mit Leib und Seele Segler. Mittlerweile ist er sogar mit seinem Hausstand auf sein 22-Fuß-Schiff Bea Orca umezogen! Er erzählt von seiner Reise auf dem Schlau-Segelboot durch Friesland, sein Buch und sein neues Abenteuer mit BEA, seiner Leisure 22. Sebastian Janotta privat: Ich bin 23 Jahre alt - und mit Leib und Seele Segler. Nach zwei umzügen fürs Segeln - erst nach München (was mich da geritten hat...) und dann schließlich nach Cuxhaven, an die Nordsee - bin ich jetzt endlich auch auf mein 22 Fuß Segelboot gezogen. Neben meiner Vollzeitstelle in einem chemischen Labor verbringe ich sehr viel Zeit damit meinen Blog www.seglen-ist-leben.de zu betreiben. Wie bist Du zum Segeln gekommen? Angefangen mit dem Segeln habe ich 2012 während meiner Ausbildung. Damals kam ich gerade ins vierte Lehrjahr und wollte endlich malwieder im Urlaub was unternehmen. Durch einen Tipp meiner Eltern wurde ich auf die DJH-Segelschule in Bad Zwischenahn aufmerksam, bei der ich nicht nur einen schönen Urlaub mit Gleichaltrigen verbringen konnte, sondern auch noch den SBF Binnen machte - und mich mit dem Segelvirus infizierte. Charterst Du? Irgendwie ist es bei mir nie wirklich dazu gekommen. Abgesehen von ein paar gemiteten Jollen auf Seen in Bayern habe ich nie gechartert. Nach einem Jahr in München ging es zurück nach Rheinland-Pfalz, wo ich mir bald mein erstes Boot - BEA, ein 8 Fuß Schlauchsegelboot - kaufte. Mit ihr ging es nicht nur auf nahe Baggerseen sondern auch für mehrere Törns nach Friesland, woraus neben meinem Blog auch mein Buch "Schnell kann Jeder", erschienen beim millemari.-Verlag entstanden ist. Möchtest Du Dir ein eigenes Schiff kaufen oder hast Du vielleicht bereits eins? Mittlerweile bin ich bei meinem zweiten Boot. Nach meinem Umzug aus dem Binnenland an die Nordsee war klar, das ich etwas neues Brauche. BEA, so toll sie auch ist, war einfach für die Nordsee denkbar ungeeignet. Nach einiger Suche habe ich mich schließlich für eine Leisure 22 entschieden. Nach zwei Urlaubs- und ein paar Wochenendttörns im Sommer und Herbst 2016 bin ich im Januar 2017 dann auch Vollzeit aufs Boot gezogen. Sie ist somit mittlerweile im wahrsten Sinne des Wortes mein Zuhause. Hast Du ein Traum-Schiff? Ganz ehrlich? Aktuell bin ich mit meiner Leisure 22 absolut zufrieden und will gar kein anderes Boot. Selbst wenn das Geld da wäre - ich würde es lieber nutzem zum Segeln. Wenn ich mich aber nach einem größeren Boot umsehen würde wäre entweder ein langes Plattbodenschiff mit wenig Tiefgang oder, fast noch lieber, eine Ovni 28 ein heißer kandidat. Aber wie gesagt: Ich bin noch immer absolut begeistert von der Leisure 22 und plane aktuell keinen Törn, den ich ihr nicht zutraue. Da ist er der Skipper das thema.... Welches Revier befährst Du im Moment am liebsten? Ich mag raue Reviere, Orte die nach Abenteuer riechen. Somit fühle ich mich auf der Nordsee sehr wohl. Wenn Geld keine Rolle spielte, wie sähe Deine seglerische Zukunft aus? Schwierig. Wenn Geld keine Rolle spielen würde? Ich nehme an ich würde - ganz langsam - Nordeuropa besegeln. Ostsee, Nordsee, Nordatlantik und hoch nach Nordnorwegen bis ins Nordpolarmeer. Anfangen würde ich aber aktuell ganz klar - im Wattenmeer. Welches ist Dein Lieblings Gegenstand am Boot oder welches Teil magst Du besonders und warum? Das hängt immer ganz von ab. Im Moment ist mir tatsächlich meine kleine Heizung am wichtigsten. Im Winter ist sie vielleicht das elementare Ausrüstungsstück. Für mal eine Woche ohne mag dies auch ohne gehen - ich habe ja bei Temperaturen um den Gefrierpunkt schon bei meinem Wintertörn mit BEA draußen gezeltet - aber wenn man an Bord lebt sollte ein wenig Komfort doch sein. Dies ist einer der Gründe, weshalb ich mir noch eine zweite Heizung (allerdings eine, die vom Landstrom unabhängig ist) kaufen mag. Unterwegs.... Das Ankergeschirr. Auch hier wird dieses Jahr nachgerüstet (aus Gründen!). Ankern ist für mich etwas ganz besonderes, hat es geschafft innerhalb kürzester Zeit zu einem ganz wichtigen Bestanteil des Segelns für mich zu werden.So ein Ankergeschirr eröffnet einfach ganz neue Möglichkeiten. Zudem gehört es für mich mittlerweile auch zur Sicherheitsausstattung. Meine Segelabenteuer mit BEA Mein erstes richtiges Segelabenteuer waren meine Törns mit BEA, meinem 8 Fuß Schlauchsegelboot - ein Boot, das eher für ein paar Stunden auf einem Baggersee gebaut war denn für längere Törns wie ich sie mit ihr unternahm. Während dieser Törns wurde mir recht schnell klar, das ich mehr Meer will. 2016 zog ich daher an die Nordsee und kaufte mir, nach einer längeren Suche, Bea Orca. Nach einer Testphase 2016 kam sie ende Oktober aus dem Wasser und ins Winterlager, wo ich einige Anpassungen vornahm. Am 16.01.2017 ging es dann für sie wieder ins Wasser - und für mich an Bord. Seit diesem Tag wohne ich auf ihr. Mittlerweile habe ich (für ab diesem Tag) auch meinen offiziellen Wohnsitz an Bord. Die Wohnung ist gekündigt und wird gerade aufgelöst. Welche Buchempfehlung kannst Du unseren Hörern mitgeben? Natürlich zunächst einmal mein eigenes Buch - "Schnell kann Jeder" von mir, Sebastian Janotta. Hier berichte ich von meinen Abenteuern im 8 Fuß Schlauchsegelboot. Ich war, als der Verlag auf mich zukam selbst erstmal skeptisch. Immerhin bin ich weder Segelprofi noch Langfahrtsegler! Doch jetzt, wo ich das Ergebniss kenne kann ich es begeistert empfehlen. Ein weiteres Buch ist "Mein Boot ist mein Zuhause" von Holger Peterson, erschienen ebenfalls beim millemari.-Verlag. Sowohl Inspiration als auch Information für mein Leben an Bord habe ich reichlich von Holger und aus seinem Buch bezogen. Und auch Merle Ibachs "Ostseeprinzessin" fand ich ganz toll. Unter www.gluexpiraten.de/audiobooks bekommst Du fast alle Titel als Gratis-Hörbuch im kostenlosen Probeabo. Gleich hier ausprobieren! Welchen Fehler hast Du mal auf oder an dem Schiff gemacht und was war die wichtigste Lektion daraus? Ein Fehler? Schwierig... Wobei: Selbstüberschätzung und Selbstbetrug. Beim aller erster Seetörn ging einhand von Hooksiel nach Cuxhaven. Und endete damit, das mich die Seenotretter die letzten Meter geschleppt haben, da ich kurz vor Cuxhaven gegen den Strom stand, nach 16 Stunden an der Pinne komplett übermüdet. Ich hatte mich selbst kronisch überschätzt. Einhand und ohne davor Seeerfahrung auf die Nordsee? Geht. Aber Babysteps - und nicht gleich einen weiten Schlag unternehmen. Das andere war wohl meine Beinahe-Strandung vor Neuwerk. Es stand eine ordentliche Welle in der Flachen Hafenausfahrt. Mein Bauch sagte mir ganz klar: Nicht rausfahren! Aber mein Kopf hat beschlossen den Zahlen zu vertrauen, die dafür geprochen haben das es klappen sollte. Man ist selbst vor Ort. Natürlich sollte man die Entscheidung nicht nur vom Bauchgefühl abhängig machen. Aber wenn der Bauch schon sagt das etwas eine Scheißidee ist - dann hat das meistens seine Berechtigung. Dieser Selbstbetrug hätte mich auch mein Boot kosten können - erst im letzten Monat kam ich von untiefe neben dem Hafen runter und zurück ins Hafen. Ich war im wahrsten Sinne des Wortes nur noch wenige Meter von der Hafeneinfahrt entfernt. Was empfiehlst Du jemandem, der mit dem Segeln beginnen oder sich weiter entwickeln möchte? Machen! Unbedingt machen. Natürlich kann man erst lange Kurse machen, theoretisieren... Aber am Ende lernt man auf See. Und der Schein mit der mit Abstand steilsten Lernkurve ist der Kaufvertrag des ersten seegehenden Bootes. Aber: Langsam, mit Bedacht. Sprich, nicht als ersten Seeschlag einhand von Hooksiel nach Cuxhaven. Sondern kleine Schläge oder Schläge, bei denen es viele Möglichkeiten gibt kurzfristig den Tag auf dem Wasser zu beenden. Gut geeignet dafür sind zum Beispiel die Niederländischen Binnenreviere. Aber es geht auch auf der Nordsee. Eben da, wo man künftig segeln will. Welchen „letzten Tipp“ kannst Du uns und unseren Zuhörern mit auf dem Weg geben? Vergesst "so groß wie möglich". Den Tipp findet man hundertfach im Internet und hört ihn auch in Gesprächen immer wieder. Ich glaube ehr an "So klein wie möglich, so groß wie nötig". Natürlich kann man das Boot im Nachhinein nicht vergrößern. Aber eben auch nicht verkleinern. Jeden Fuß, den so ein Boot länger wird, wachsen nicht nur die Kosten sondern auch der Anschaffungspreis. Bereits ein vergleichsweise kleines 22 Fuß Boot wie meines kann sehr seegängig und zugleich wohnlich sein. Wem dies, so wie mir reich, der sollte sich nicht einreden lassen er bräuchte dreißig oder gar vierzig Fuß. Ein weiterer Vorteil: Man kann es sich früher leisten - und somit früher seinen Traum leben. Ich plädiere ganz klar dafür, as Leben so weit wie möglich zu vereinfachen um jetzt glücklich zu sein, statt in einer viel zu oft fernen und ungewissen Zukunft. Wie kann man Dich erreichen, wenn man Fragen an Dich hat oder mit Dir in Kontakt kommen möchte? Am besten über meinen Blog www.segeln-ist-leben.de oder meine Facebookseite. [newsletter]

Stream "Wick To Handle" Here: https://soundcloud.com/59xrecords/heathersett-wick-to-handle/s-WlvVTcQQpz2 “I started a band, played some shows, started recording, and then the world went to hell.” says Heathersett vocalist/bassist, Craigan Hogeland. The fall of 2019 was met with much optimism for the members of Heathersett (Craigan Hogeland – Vocals/Bass, Juergie Landstrom – Vocals/Guitar, Andy Torrey – Guitar, and Zack Mulazzi – Drums). Little did anyone in the world know what 2020 had in store. Fast forward a year later, and Heathersett is ready to debut their first single, “Wick to Handle” off their self-titled LP due out in 2021 on 59 X Records. Not all news is bad news these days. Hogeland found himself in a new relationship that influenced much of his songwriting on Heathersett's debut LP. “Wick to Handle is just a love song about waiting for your future significant other to become available.” - Craigan Hogeland (Vocals/Bass) “Wick” clocks in right around 3:44 with an upbeat rhythm and contagious lyrics that will transport the listener back to simpler times. Landstrom and Hogeland's back and forth, melodic yet angsty vocals pay respect to bands like Taking Back Sunday and Four Year Strong while seeking guidance from legends like The Beach Boys and The Beatles. “We wrote Wick while essentially still introducing ourselves to each other. The first half is an olive branch; an attempt at conciseness so that we could all start this project on common ground. The second half is a swan dive into what I think makes our band great: If we don't feel like coming back to the chorus because we found something more fun, then sayonara!” – Juergie Landstrom (Vocals/Guitar) This episode is proudly brought to you by: #Betterhelp : https://www.betterhelp.com/sipod for 10% off #H2one #Handsanitizer : https://h2one.com/ BUY MERCH!!!!! #Merch Store: https://www.dckproductions.com/shop Follow me: https://www.instagram.com/suckitpodcast https://www.facebook.com/suckitpodcast https://www.twitter.com/suckit_podcast --- Send in a voice message: https://anchor.fm/thedarksideofmusic/message Support this podcast: https://anchor.fm/thedarksideofmusic/support

Episode two of the Career Chat series.

Great interview with Ann Landstrom, Award Winning Master Photographer. Ann has studied with the best, including top Playboy Magazine photograhers to learn the proper angles and lighting to maximize capturing the female body and physique. Ann also has her therapeutic dog - she calms people down when they go her to studio - Luna.You can find Ann at:Ann Landstromwww.annphotography.cominfo@annphotography.com(760) 610-6263San Diego, California Gift - Personal Branding Guidehttps://www.annphotography.com/form/branding-magazine#photography #photographer #awardwinning #Luna #AnnLandstrom #award #podcast #thatgalwiththatguy #iamthatgal #spotify #applepodcast #googlepodcast #stitcher #itunes

Rima interviews Ann about her journey going from a verbally abusive marriage and homelessness to a successful award winning photographer who empowers women. Ann Landstrom is an award winning master photographer with over 20 years in the photography industry. She has photographed public figures and influencers and has been featured in San Diego magazines, numerous podcasts, and the Huffington Post. Ann specializes in Branding, Boudoir and Fine Art Portraits, her passion and drive is to bring out the best version of each of her clients to elevate their business and also their self-esteem. To show them their inner shine and essence they might have forgotten about or never seen in themselves before through her transformational lens.

[Interview starts at 45:51] This week's podcast was recorded prior to Covid 19 but I sat on it for awhile because it was about saltwater fly fishing in the San Francisco Bay area and I wanted to wait until sheltering at home restrictions were eased a bit and people could get out to try these ideas.  Sarah Landstrom of Lost Coast Outfitters regularly leads trips for this accessible and interesting urban fishing, and she has some great tips, and even suggestions for locations to try.   In the Fly Box this week, we have a number of interesting questions--plus a great e-mail from a listener on how he successfully uses two-handed rods for nymphing in Alaska.  Some of the questions this week are: Do you think planning a trip with a guide will help me learn new skills? What is the best way to go about asking for permission to fish on private land? I don't have much time to fish.  How can I streamline things and become more efficient so I don't spend all my time rigging and tying knots? Do you think a surgeon's knot is visible to fish? Where on my leader do I put my indicator? Why can I hook trout on dry flies? What locations, flies, and weather conditions are best for night fishing? Should I use mothballs in my fly tying materials? Should I microwave my fly-tying materials?

Join Shannon as she interviews Kelsey Landstrom, human rights advocate, community organizer in reproductive rights, freedom of choice, and health care in the human trafficing fields.This is the 1st interview in the series of real individuals serving others about what have we learned together! Kelsey shares her lessons about uncertainty, scarcity vs. abundance, and what has added joy, peace, gratitude and myrth to her own life. She shares these from her current state of completing graduate work without a job waiting for her in this COVID climate.The two discuss the strategies Kelsey uses in mindfulness and presence to meet difficult emotions that anyone can use. You'll hear larger lessons too that we all can connect to about compassion, connection, love and TRUST in the process when the future is uncertain! She is choosing collaboration over competition and choosing abundance over scarcity - let's get inspired together!Support the show (http://www.innerpeacerising.com)

On this week's episode - Jenna interviews Taylor McNair, Miss Rodeo America 2019! Taylor is 23 years-old and the third Miss Rodeo Mississippi to wear the coveted crown. In addition to the title of Miss Rodeo America 2019, Taylor earned the Appearance, Personality, and Written Test awards along with the Sherry Smith Memorial Scholarship, third place for her scrapbook and was the winner for the Chap Award. In 2017, Taylor earned a Bachelor of Science in Agricultural Business with a concentration on Policy and Law from Mississippi State University. While attending MSU, she also competed on both the Equestrian and Rodeo teams. Taylor plans to enhance her strong voice for agriculture by pursuing a Doctor of Jurisprudence degree with a Master of Law in Agriculture and Food Law. During her reign as the official representative of the Professional Rodeo Cowboys Association, McNair will travel around 100,000 miles and appear at nearly 100 rodeo performances. Along the rodeo trail she'll make appearances at schools, civic groups, and other special events. Attendance at these events is to educate the public and create awareness about the sport of rodeo, its sponsors, and its opportunities. Taylor will also serve as a spokesperson at a variety of promotional events and model in advertisements for key brands, sponsors, and publications of the Western industry. Taylor is beyond thrilled to wear the Landstrom's Black Hills Gold crown as it has been a dream of her's for many years. Long Live Cowgirls. Follow her journey on social media - @MissRodeoAmericaOfficial

This week on the Exercise Is Health podcast, Julie and Charlie sit down with Dr. Matthew Landstrom from the Landstrom Center in Schaumburg. Dr. Landstrom is a Clinical Neuropsychologist specializing in the assessment and treatment of children, adolescents, and adults with psychological, neurological, and neurodevelopmental disorders. He developed his unique treatment approach while serving as the Clinical Director of an adolescent and young adult substance abuse/dual diagnosis and mental health treatment facility, whereby a greater understanding of a patient’s cognitive functioning and capabilities was utilized to increase the efficiency and efficacy of treatment, as well as improving the chance of sustained recovery and ultimate outcomes.  Check out all of the details in this week's episode!

Wir sind in den Osterferien noch für ein paar Tage auf den Bauernhof Campingplatz Kirnermarteshof in Oberried. Da wir schließlich einen recht großen Akku an Board haben, können wir auf Landstrom verzichten und das Geld einsparen. Und da ist es dann passiert. Als ich morgens auf den Ladestand schaute waren es noch knapp 20%. Am Abend zuvor waren es noch +-90%. Wie konnte das passieren das der Akku über Nacht quasi leergezogen wurde?   Inhalte Wie ist unser Aufbau Kühlschrank zieht den Akku leer Was lernen wir daraus Links rund um unseren Akku: 088 – Einkaufstipp für LiFeYPO4 Akkus 089 – Warum einen Akku im Wohnwagen und warum ausgerechnet einen LiFeYPO4 Akku? 109 – Sommerferien ohne Landstrom unterwegs – LiFe Akku sei Dank   Podcast-Business Podcast Der Podcast wo es ums Podcast machen geht. Von der Pike auf erkläre ich was es alles benötigt um einen Podcast zu starten und als Markektingkanal für das eigene Business zu nutzen. Dieser Podcast ist für Selbstständige und Unternehmer interessant. Link: www.podcast-business.com

Selbst ohne Landstrom ist es möglich mobil an 230V zu kommen. Es gibt auch Geräte welche unbedingt mit 230V versorgt werden wollen. Somit stellt sich die Frage wie das am besten zu bewerkstelligen ist. In Wohnmobilen oftmals bereist eingebaut und in Wohnwagen eher selten anzutreffen sind die Wechselrichter. Diese elektronischen Geräte schaffen es zum Beispiel aus 12V Gleichstrom, 230V Wechselstrom zu machen. Jedoch gibt es bei den Wechselrichtern wichtige Unterschiede welche man kennen sollte.   Inhalte: Warum 230V ab und an notwendig sind Welche Typen an Wechselrichtern gibt es Welche Leistung sollte ein Wechelrichter liefern Welcher Wechselrichter ist denn nun der richtige Was habe ich verbaut Hier der Link zu meinem 300W Wechselrichter: https://amzn.to/2SI3ZFK*   Camper on Tour im Netz ► Website ►Online-Shop ► Instagram ► Facebook ► Pinterest     PS: Mit * markierte Links sind Affiliate-Links. Euch entstehen keine Kosten. Ihr unterstützt damit meine Arbeit am Podcast. Vielen Dank für das verwenden der Affiliate Links.

In den Sommerferien kommt der LiFe akku nun zum ersten mal so richtig zum Einsatz. Aber: Wie ist es denn nun so mit einem Akku unterwegs zu sein. Ohne die Notwendigkeit von Landstrom? Reichen 100W Solar oder nicht? Was fehlt noch an "Bauteilen" Wie viel Geld "spart" man   Camper on Tour im Netz ► Website ► Instagram ► Facebook ► Pinterest

Im allgemeinen trifft es eher die Wohnwagenbesitzer, aber auch mit dem Wohnmobil kann man sich an den Landstrom hängen. Daher ist das sich "anhängen" an den Landstrom für viele was ganz normales. Ein langes Kabel an beiden Enden eingesteckt und zack hat man 230V. Was oft vergessen oder nicht beachtet wird ist, das auch hier gewisse Regeln und Vorschriften gelten. Eine ramschige Kabeltrommel mitnehmen und irgendwie ranfrickeln ist schon mal nicht gestattet. Themen der Folge: Das richtige Kabel Trommel oder loses Kabel Adapter   Ausführlicher Artikel zur Folge: https://www.camperontour.net/folge99   Camper on Tour im Netz ► Website ► Instagram ► Facebook ► Pinterest

Für was braucht man überhaupt einen Akku im Wohnwagen? Gerade für den Wohnwagen gibt es meiner Meinung nach nur zwei Gründe für einen Akku. Der eine ist zum Einsatz eines Rangierantriebes / Mover und der andere wenn man Autark bzw. unabhängig vom Landstrom sein möchte.   Warum Wir einen Akku in den Wohnwagen einbauen Der Grundgedanke ist schon etwas älter. Die Idee der Landstromunabhängigkeit hatte ich bereits bei unserem alten Wohnwagen. Dieser hatte jedoch eine sehr geringe Zuladung. Da war dann die alternative Idee eine Stromkiste selbst zu bauen. Jetzt mit dem neuen Wohnwagen und mehr Zuladung spielt das Gewicht nicht mehr ganz so eine Rolle, wird aber trotzdem beachtet. Denn schließlich zählt jedes Kilo. :-) Bei unserem neuen Wohnwagen, einem 8,75m langem Tandemachser war von vorne rein klar, das ein Rangierantrieb nachgerüstet wird. Den die Vergangenheit hat gezeigt das es gerade auf südlichen Campingplätzen teilweise doch recht eng ist und man mit so einem langen Gespann Probleme bekommen kann. Auch sind nicht immer helfende Mitcamper zur Hand.   Wieso ein LiFeYPO4 Akku? LiFe Akkus werden sicherlich auch etwas gehypt, keine Frage. Aber die Vorteile sind auch wirklich unschlagbar. Hier ist ganz klar das geringe Gewicht im Vergleich zur nutzbaren Kapazität und der langen Lebensdauer. Demgegenüber steht der hohe Anschaffungspreis. Aber der Reihe nach, am Beispiel unseres neuen 160Ah LiFe Akkus. Für folgende Auflistung nehme ich nun einen Solar AGM Akku bzw. einen Gel Akku. Dieser soll jeweils stellvertretend für alle gängigen Akkus stehen. Klar gibt es auch hier Unterschiede. Ich möchte einen groben Überblick geben. Alles bis ins letzte Detail zu beleuchten würde den Rahmen vermutlich massiv sprengen. Gewicht: Unser LiFe Akku wiegt in etwas 30kg. Ein AGM Akku mit 160Ah wiegt in etwa 45kg. Das sind schon mal rund 15kg weniger an Gewicht Nutzbare Kapazität: Einen LiFe Akku kann man bis 90% seiner Kapazität nutzen. Das entspricht in etwa 144Ah. Eine Solar AGM, so habe ich auf diversen Seiten gelesen, soll man nicht tiefer als 50% entladen. Das entspricht somit 80Ah. Lebensdauer: LiFe Akkus haben eine enorm hohe Lebensdauer in Bezug auf die Zyklenzahl. Diese übersteigt die Lebensdauer (anhand der Zyklenzahl) um ein vielfaches eines AGM Akkus. Somit muss man öfter Geld investieren um sich neue Akkus zu kaufen. Eine Ausnahme ist hier im Vergleich zum Bsp. eine Victron Gel Long Life welche bei 30%iger Entladung eine Zyklenzahl von etwa 4500 Zyklen bietet. Eine LiFeYPO4 hat bei 80% Entladung eine Zyklenzahl von 5000 Zyklen und bei 90% noch 3000 Zyklen. Selbstentladung: LiFe Akkus haben eine weitaus geringere Selbstentladung als AGM Akkus oder sonstige herkömmlichen Akkus. Dies ist mir bereits von meinen LiPos aus dem Modellbau (Quadrocopter) bekannt. Die Dinger kann man aufladen und ewig liegen lassen ohne das da signifikant Ladung verloren geht.   Zusammenfassung: Um das ganze mal grob über den Daumen zu berechnen nehme ich nun mal unseren 160Ah LiFe Akku und zum Vergleich eine Solar AGM und einem Gel Akku. Wir haben eine maximal nutzbare Kapazität von 144Ah (90%). Dies kostet uns 30kg an Gewicht und wenn man den Akku bei Faktor kauft 1145€ (Akku plus Verbinder). Da ich meinen bei ev-power gekauft habe, habe ich summa summarum nur 650€ für den Akku inkl. Teile bezahlt. Um mittels AGM Akkus auf diese nutzbare Kapazität zu kommen benötigen wir 288Ah Akkus, bei angenommener Entladung von 50%. Eine "Offgridtec 260Ah AGM" wiegt 74kg und kostet 460€. "Offgridtec Gel 200Ah + 50Ah" wiegen zusammen 74kg und kosten 510€. Somit kostet ein LiFeYPO4 Akku in etwas 2-3 mal so viel wie AGM oder Gel Akkus, wiegt aber weniger als die Hälfte und die Lebensdauer übersteigt diese bei weitem. Somit muss man AGM oder Gel Akkus häufiger neu kaufen als einen LiFe Akku. Somit ist der Anschaffungspreis eines LiFeYPO4 Akkus zunächst hoch, amortisiert sich jedoch über die Jahre.   Das war jetzt mal ein grober Überblick bzw. Einblick wie es zu der Entscheidung kam einen LiFeYPO4 Akku anzuschaffen anstatt einen AGM oder Gel Akku. Es war die Gewichtsersparnis und langfristig betrachtet spart man Geld. Man muss es ja auch so sehen das man permanent weniger Gewicht rum fährt was einem minimal niedrigeren Spritverbrauch mit sich bringt. Auch ein Punkt wo man den ein oder anderen Euro spart.   Hier noch die Links zu allen genannten Akkus Bei den LiFeYPO4 Zellen benötigt man jeweils vier Stück! Faktor 160Ah LiFeYPO4 Zellen: http://www.faktor.de/batterien-einzelzellen/einzelzellen/winston-3-2v-monozelle/lyp160aha-lifeypo4-wide.html ev-power 160Ah LiFeYPO4 Zellen: https://www.ev-power.eu/Winston-40Ah-200Ah/WB-LYP160AHA-LiFeYPO4-3-2V-160Ah-WIDE.html?cur=1 Offgridtec 260Ah AGM: https://www.offgridtec.com/batterien/agm-batterien/offgridtecr-agm-260ah-20hr-12v-solar-batterie-akku-extrem-zyklenfest.html Offgridtec 200Ah Gel: https://www.offgridtec.com/batterien/gel-batterien/200ah-gel-batterie.html Offgridtec 50AH Gel: https://www.offgridtec.com/batterien/gel-batterien/offgridtecr-50ah-c20-gel-akku-12v.html LG Dominic    

Transcript of the February Podcast, “Getting Personal: Omics of the Heart”, Episode 13   Hosted by Jane Ferguson   Assistant Professor at Vanderbilt University Medical Center & Associate Editor of the Circulation: Precision and Genomic Medicine journal of the American Heart Association Jane Ferguson:             Hello. This is episode 13 of Getting Personal: Omics of the Heart. It's February 2018. I'm Jane Ferguson, an assistant professor at Vanderbilt University Medical Center, an associate editor at Circulation: Precision and Genomic Medicine, and an occasional podcast host. This month, I talked to Kiran Musunuru and Svati Shah about how they spearheaded name changes for Circulation Cardiovascular Genetics and for the AHA Council on Functional Genomics and Translational Biology, and Andrew Landstrom talked to Kaytlyn Gerbin and Brock Roberts from the Allen Institute about some extremely cool work they are doing with CRISPR and IPS cells to create fluorescently tagged maps of live cells, which allowed them to image and better understand the structure and function of individual cells.                                     I'm delighted to have two guests on the podcast today, Dr. Svati Shah is the current chair of the AHA Council on Genomic and Precision Medicine formerly called the Council on Functional Genomics and Translational Biology. She is an associate professor of medicine at Duke University Medical Center. Dr. Kiran Musunuru is editor in chief of Circulation Genomic and Precision Medicine formerly named Circulation Cardiovascular Genetics, and he's an associate professor of medicine at the University of Pennsylvania Perleman School of Medicine.                                     Dr. Shah and Dr. Musunuru were kind enough to take time out of their busy schedules to join me for a joint discussion on the recent enhancement of name changes for our council and our journal. With tight schedules and last-minute flight cancellations we didn't have ideal settings for recording, so apologies in advance for a little more background than usual.                                     My instruction highlighted a number of name changes and astute listeners will have noticed that the new names for both the journal and the council are very nicely aligned, so I know this was not a coincidence, and I'd love to hear from both of you, what prompted the decision to change the respective names of the council and the journal, and how did you come together to streamline these name changes? Svati Shah:                   Well, maybe I'll take a first start, you know, we, we're really lucky in our council, we have a very, you know, certainly one of the smaller councils [inaudible 00:02:26] we have a very collegial spirit that wants to get things done. So, these conversations actually started probably three years ago, umm, when Jen Howell was chair of the FGTB council. And we realized that not only was our constituency broadening in expertise and breadth and depth, but also, umm, the desire to kind of move beyond the really wonderful work the council is doing around technology platform, genomics, genetics and you know important advances in many of our council members have made in the translational biology field and really thinking about the fact that we have this amazing expertise that can come together across a wealth of disciplines to really translate what's being done in the omic space, and apply it in this new world of precision medicine.                                     And so, umm, that is what stirred really thinking about a name change so that not only would it reflect this expanding constituency in expertise and hopefully draw even more people, across the, you know, wide expertise. But also to harmonize more with people who are in other councils, including clinical cardiology, and people that, really, in the end we are actually quite allied with scientifically, but perhaps those councils didn't recognize really what our council was about because of our previous name. So in that context, you know, it's been wonderful. Kiran has been a wonderful partner in all of this, he's been a real leader in the council and over the past two years we have had many conversations across council leadership and the entire council, and thinking about what this name change would be. And actually, it was almost a consensus amongst council leadership to choose Genomic and Precision Medicine as the name, really to reflect our core beliefs and our core science in genetics and genomics, but also to reflect the expanding expertise of all the different omics platforms, our expertise in clinical genetics with more genetic counselors joining our council, and our expanding expertise in computational biology. And this really allied nicely also with the American Heart Association building a very important institute, the Precision Medicine Cardiovascular Institute. So, I'll let Kiran go from here but again, Kiran has really been a great partner in this and he can kind of expand on that story and how that led to the journal name change. Kiran Musunuru:         Sure, so, with respect to the journal, I think these changes have been growing for a while. I think a lot of the same considerations came into play, the feeling that the journal with the name Circulation Cardiovascular Genetics was perhaps too narrowly defined given how the field, how the science was evolving. And the other consideration is that the Functional Genomics and Translational Biology Council has had a journal, a companion journal if you will, all of this time with a fairly distinct name, Circulation Cardiovascular Genetics, and so it wasn't necessarily obvious to those who are not on the inside so to speak that there was supposed to be a very tight connection between council and journal, that the journal really was the journal of the council and so in the process about deliberating about a council name change, it became natural to think that, "Wow, wouldn't it be nice if the journal could execute a similar name change", and separately, even though this predates my tenure as editor of the journal there had been conversations going on separately or independently that perhaps the journal would benefit from signaling that it was not just about cardiovascular genetics in the very narrow sense, but was really about a much larger area of science. And so there had already been contemplation for quite a while about a name change and so when I assumed the editorship I didn't really have to do much to convince anyone that this would be a useful thing.                                     The scientific publishing committee of the American Heart Association and all the various people involved publishing the journal were already sort of primed for a name change and then it just ended up being a nice convergence of opportunities, Svati with her work in the council and really showing the leadership to lead the transition from Functional Genomics and Transitional Biology to Genomic and Precision Medicine.                                     That really laid the groundwork, and because it was such a deliberative process, such an inclusive process, involving dozens of people on the leadership committee of the council as well as general membership of the council, it was really a no-brainer. The hard part had already been done, the thinking had already been done and I was straightforward to say that we should change the name of the journal to match, Circulation Genomic and Precision Medicine. Jane Ferguson:             Have there been any logistical difficulties in getting this name change through, or has it all happened very organically? Svati Shah:                   The American Heart Association has been a real partner in the name change, sometimes things require many layers of approval and in fact, it has been a relatively seamless process. We came up with a consensus around the name change and later applied formally for that change in the council name, and that was pretty quickly approved by the Scientific Advisory Committee, within a few months really. Our name change became official and we are in the exciting time now of advertising and kind of marketing the name change and appeal to a broader constituency and really reach out to group that perhaps wouldn't have realized that this council is a great home for them again thinking of genetic counselors and computational biologists. So, it really, you know, has been a surprisingly seamless and fun process. Kiran Musunuru:         As I mentioned before it was already kind of in the air that a change was imminent and so when I posed the name change to the Circulation Genomic and Precision Medicine it ended up being a very smooth transition. It was timed so that the volume change, that is changing from the volume associated with the calendar year 2017 to the volume associated with the calendar year 2018, January first ended up being a very logical transition time and so that's when the change occurred.                                     And happily, the council name change ended up occurring almost in lockstep; whereas, you know within a few weeks of the journal announcing its name change the council was able to announce its name change as well. I think that has had a reinforcing effect across the American Heart Association and its membership. It really signals that the council and the journal are tightly tied together, are partners in moving in lockstep. Jane Ferguson:             Svati, this question's probably more for you, so what does the name change mean specifically for existing FGTB council members, and what if anything will change, and then what might it mean for potential new members who are trying to decide what council to join? Svati Shah:                   That's a great question, Jane, you know I am a pragmatic person and I think our council also reflects that pragmatism. We get a lot of things done and we, I think, spiritually all agree that we shouldn't just change the name just for the sake of changing the name. And so we really, actually the name change followed [inaudible 00:10:18] were involved in, these discussions are a year and a half of really thinking about what direction we wanted the council to go and then what the sort of short and long term goals of our council are and then how does the name change effect the long term goals.                                     So, we have a lot of great initiatives in the short and long term, which again will capitalize on our broadening expertise in these different clinical genetics and precision medicine and really, translating genomic and omic findings into, into important patient care. And so, we have several things coming down the pipe that are sort of proof of principle examples of what the name change reflects.                                      So, one example is that we are now working on developing a certificate in medical genomics with the idea that we really need more genetics education. Our council has been very much embedded in genetics and genomics education, Kiran being a key example of that. And now we are expanding that into thinking about how genomics is applied to clinical medicine but making it at the level that is digestible and understandable and is easily applied by a general cardiologist and even primary care doctors will be able to use that resource. And the idea is this will be your self-sustaining certificate that's given through the American Heart Association, so we have a group that's been working on that certificate and hopefully that will be coming out soon.                                     Another key component of what we're doing is trying to reach out more and partnering with other associations including the American College of Medical Genetics and the National Society of Genetic Counselors, again really thinking about how we transition our important scientific discovery work into translation implementation science around patient care.                                     To give you some examples of what that means in terms of what the name change is reflecting, I think with the right use, for the second part of your question, which I think is a really important part of your question is, we want to attract more people in the computational biology field, in the precision medicine space, in the clinical genetic space and again reaching out to genetic counselors through some of these societies, because we, just the wave of precision medicine is here, is going to expand even more and the expertise within our council that was already there but that now we can expand. I think it will be leveraged to really make important contributions to making sure that those efforts in precision medicine are done well, or done responsibly and are done with the patient in mind because in the end the American Heart Association is at the forefront of patient advocacy group.                                     This is a really exciting time, I think that, you know, however you want to define precision medicine the bottom line is precision medicine is here and we can't have, it's not going to be a single faction of individuals or a single expertise that is really, is going to be able to leverage fundamental scientific discoveries whether its genetics, genomics, metabolomics, proteomics, and really translate them responsibly into patient care, so it's going to involve an interdisciplinary and multi-disciplinary effort.                                     I feel really proud that I'm part of the AHA and that we sort of have this perfect storm between Kiran's leadership in the journal, our council changing, you know, its goals and its name aligning with the Institute for Precision Cardiovascular Medicine within the AHA. And I think that, you know, it's not all rainbows and sunshine. We have a lot of work that is cut out for us in the next few years to figure out ways that we can tangibly and concretely, and again responsibly, work together across each of these three components of this perfect storm to make sure that it’s not just a glitzy name change and that there is actually substance and behind all of it, so, you know, it will be, there will be challenges, there will be obstacles, but I think that the amazing people within each of those three components, I feel very confident that we are going to be able to do it well. Jane Ferguson:             Yeah, I agree, as a member of the council, if anybody can do it I think this group of people can do it, so it's very exciting to see, so thank you both for joining, and congratulations again on the new names. It's really exciting to see these, you know, new directions for the council and the journal working together. And I really look forward to seeing all the great initiative that will be coming out in the next few years. Svati Shah:                   Thank you, Jane. Kiran Musunuru:         Thank you, Jane. Andrew Landstrom:     My name is Andrew Landstrom, and I'm an assistant professor in the department of pediatrics section of cardiology at Baylor College of Medicine. I'm a member of the early career committee of the American Heart Association Council on Genomic and Precision Medicine, previously the Council on Functional Genomics and Translational Biology, and I'm joined today by Brock Roberts and Kaytlyn Gerbin, who are scientists on the stem cell and gene editing team at the Allen Institute.  Here to discuss a little bit more about CRISPR editing and what they have done for live cell imaging using fluorescent proteins.                                     So, Brock and Kaytlyn, I'm hoping you can discuss a little bit about what the Allen Institute is and your overall research mission and goals.  Kaytlyn Gerbin:           Yeah, great, so this is Kaytlyn and thanks Andrew for having us on, and we're really excited to share a little bit of the information about what the institute is doing, because we're building a bunch of tools that we think would be really useful for the research community. So, we're excited to get the word out there. And so, the Allen Institute is a non-profit research institute, and we're based in Seattle, Washington, and, essentially what we're trying to do is better understand the cell.                                     We want to understand the various states the cell can take based on structural organization of how different organelles work together. And so, we're doing this, essentially by live cell imaging and also combining that with predictive modeling so that we can build tools to be able to understand structure-function relationships and how cells behave in a healthy state or in a diseased state. So, you can kind of think of this as, we like to say sometimes like a Google Earth for the cell, so if you kind of think about it in that context, a lot of times, you know you could look at the cell at a really high level just like you could look at the Earth at a very high level. Then you could zoom in further and you could look at an individual pathway maybe that you're interested, or perhaps, as an analogy, like a different highway within a part of a city.                                     But you don't really understand how all that works together and how the city functions together until you start to put in things with spatial organization, or maybe temporal dynamics, or how different parts of the structures, or different structures and organelles work together to form the unit that is the cell.                                     And so, essentially, we're trying to generate a bunch of data so that we can build predictive models to help us understand that better. And, we're doing this with human induced pluripotent stem cells, and the first cell state or cell type that we're studying is cardiomyocytes after differentiation.                                     And so, yeah, as we're kind of generating this data we are a non-profit institute, and all of our lines and our plasmids, protocols, data, pretty much everything that we make is becoming publicly available as it passes QC. And so, yeah, we're excited about that, I don't know if, Brock, you have anything else to add. Brock Roberts:             Yeah, just I think an important concept that we're often working with is scale. And, biology exists at certain scales, and that's certainly true for cells and the Google Earth analogy holds.                                     You know, at some level if we want to understand the cell at the scale of its entirety, but we have to kind of cut that down and understand cells at the level of its parts.  And, they're working together as we know, and can infer, but we try to find a way to look at the part one by one and then put it all together in a model that's predictive. And the predictive part is going to be really important. Much like Google Earth can allow us to, you know, look at a traffic pattern in the city or something like that once the data is filled in. We hope to fill in enough data by looking at the cells constitutive parts to make the predictive model. Andrew Landstrom:     And not only looking at, sort of, constitutive parts, you're doing this in a physiologic live cell, so really it's Google Earth, but it's Google Earth in real time as cars are driving down the freeway and people are walking down the street. Brock Roberts:             Right- Kaytlyn Gerbin:           Yeah, exactly. Brock Roberts:             Yeah, that, that's where the dynamics of the cell can really come to life if you've prioritized looking at live cells, which are obviously incredibly dynamic. Andrew Landstrom:     And so, you know to be able to accomplish this, you all have come up with some pretty novel methods. Would you talk a little bit more about your CISPR editing approach, and how you've applied this to different lines and to get, sort of, different markers into cells? Brock Roberts:             Right, sure, the, we should say that we owe a lot to the development of CRISPR-Cas9 editing, which preceded us by a few years, but we've tried to kind of scale it up in some important ways.  And, really the important thing to appreciate about this process is it's a way to make a very precise, precisely guided DNA break in the genome of a cell. And we do this in human induced pluripotent stem cells, and so we can quite precisely choose a position or location in the human genome and trigger DNA damage, trigger breaks in the DNA molecules that make up the chromosomes.                                      And we can do this with, kind of a highly specifically guided RNA molecule that we complex with this Cas9 nucleus molecule, and these are, very famous molecules now, over the last few years they've become very well known.                                     And the upshot of this is we can, sort of trick the cell into repairing that DNA break using the processes that are always at play in living cells to resolve breaks in DNA, but we can sort of trick that process to add something additional at a specific site. And the additional sequence that we use is a tag sequence that corresponds to a fluorescent protein after the DNA is expressed and translated. And so, what we can effectively do is tag proteins that are produced in a highly endogenous, natural fashion within cells.                                     And the proteins that we can tag in this way, using this method, correspond to some of the most canonically recognized structures and organelles within the cell. And so, at this level we try to choose proteins, tag them in this manner, and take advantage of the fact that they will localize predictably to some of the dozens or hundreds of structures that make up cells. Kaytlyn Gerbin:           Yeah, and a key thing I think to add that Brock kind of mentioned was that this isn't any over expression, we're doing all this endogenously. So it’s really like, pretty, I think that's a big advancement over what has typically been done in the past with a lot of fluorescent tagging of proteins within the cell. Brock Roberts:             Right, but what's important to appreciate is that we're using the cells endogenous copies of each protein, expressed from the genome. We've done it in about 30 different genes so far. And we have a high success rate in accomplishing this process, all the way through to completion, which is to say that we know that we can introduce a tag onto at least one copy of each gene that is, that encodes a protein that can be tagged this way, and then we can monitor the cells over several months and ensure that this doesn't have a negative consequence on their growth or on their ability to differentiate or something like that. Our quality control process. We have a high success rate so far. Andrew Landstrom:     And that's really, in my eyes, one of the key, key sort of, innovative factors of your work, in that these are endogenous proteins that are able to be expressed and then to be imaged in real time without really disrupting the underlying cellular physiology. Kaytlyn Gerbin:           Yeah, and we do care a lot about what you just said, that it doesn't have any negative effect on cell behavior because we are using these as a surrogate for understanding cell behavior in, hopefully, a normal context. And we do an extensive amount of quality control work and all of that QC data is available on our website, and then you can actually access all of our cells through Coriell and all of the QC data for all those cell lines is made available, and we've also done a pretty extensive job outlining the QC that goes into this process so that, hopefully, people will take a look at that when they look at our cells and understand what we've done, but we also hope that this will kind of help set a standard for things that other people should be looking at when they're doing editing on their own. Brock Roberts:             And we really hope that people take these cells and do experiments that we don't have the bandwidth to do, and test them in ever expanding ways and let us know and report on it. Let us know how the cells perform and their unique assets. Andrew Landstrom:     Yeah, and I think all that sort of transparency with the quality control really makes it user accessible and just sort of invites that degree of collaboration, that's great. Kaytlyn Gerbin:           Yeah. Brock Roberts:             Yeah, we hope so. Yeah, we think so, too. Andrew Landstrom:     So how many cell lines do you have available? Kaytlyn Gerbin:           Yeah, so, currently, and again you can access all these lines on the website, but we have 16 lines that are released that have gone through the full QC process. Those are available now, and we have another six that are listed as in progress, which means that they will be released very soon.                                     Just to give you a few examples, so again, we're tagging proteins to label organelles in the cells. So, a lot of times, you know there's a lot of different kinds of proteins you could use to tag an organelle, so we've chosen a subset of those. So, we've tagged, for example, Tom20 to label mitochondria, Lamin-B1 for the nuclear envelope, alpha tubulin to look at micro tubules, and we also have started doing a lot more endosomal trafficking pathways, so like the endosome, lysosome, peroxisome, for example, and then a few other epithelial markers such as tight junctions, desmosomes, and actin.                                      And so, there's a kind of a bunch of structures. Those are just some examples of what we've been starting with tagging, but one of the reasons why we chose to use induced pluripotent stem cells for this whole model is because they do have the ability to differentiate into many cell types. And, I mentioned earlier that we chose to start with cardiomyocytes as a key cell type to look at, and so all of our cell line, as part of the QC process go through a cardiomyocyte differentiation protocol. And that kind of helps us ensure that the cells are pluripotent and that they can become a defined cell type and that the structure that we've labeled still is present in that differentiated cell. But it also means that we can start looking at some really interesting things in terms of how these structures change during differentiation and change from the stem cell state to the cardiomyocyte state. And so, one thing that we really started doing towards the end of last year, and we have lines coming out, hopefully soon on some cardiac specific tags. And so, to give you a few examples of things that we're working on, we have cardiac troponin I 1, and this I think will be available, I think it's passed QC and will be available pretty soon. And then we also have, we're working on sarcomeric alpha-actinin, titin, some gap junctions so that connexin 43, and then also starting to do a few signaling pathways and one that is of particular interest for the cardiomyocyte field would be beta-catenin for Wnt signaling.                                     So, we are kind of expanding on that list as well. So, we're really excited to start looking at these cardiac structures in the cells. Brock Roberts:             One way to summarize kind of, our strategy and one thing unites all of the different gene and protein targets that we have produced and focused on so far is to really think about the product gene or the protein as a reporter for an organelle or a structure in the cell. So, there are of course an extraordinary number of genes and proteins using this method, and there are many different justifications that would fly for why you would target a particular molecule, a particular gene, a protein of interest, but, what we really try to focus on are proteins that serve as a reporter for a structure.  Andrew Landstrom:     So, have you tagged any ion channels? Brock Roberts:             We have several targeting experiments that are, that take advantage of tagging the transporter molecule. One that is available is a transporter in the mitochondria, a transporter to the outer membrane, Tom20. And we're also making connexin 43 available for gap junctions. These proteins that function as trans-membrane transporter molecules accommodate the approach quite well.                                     Another that is a bit further behind, but we hope to make available before too long would be marker of the sarcoplasmic reticulum and cardiomyocytes. This is a serca protein. Andrew Landstrom:     So, with all these cell lines at your disposal, you've spoken to, sort of, the dynamic changes that occur both in differentiation of cardiac myocytes and cellular development and cell physiology, what are some other thoughts that you have that these lines might be able to show us? What are some fields that might be immediately informed by these models? Kaytlyn Gerbin:           I mean, I guess just kind of on a big pictures I think that having the ability to study live cells and look at different structures in the cell will help us better understand structure-function relationships. So I think that in cardiomyocytes that, you know, makes a lot of sense, but I think even just in the stem cell field, being able to understand how localization of a particular organelle corresponds to a different state that the cell might take.                                     And so we kind of are thinking about a lot of these different stages and states that the cell can pass through and how do we characterize that based on just kind of at a healthy or just kind of quiescent state, and then comparing that to different protivations, so looking at disease or maybe change in time, change in mutations, drug response, response to stress and how are the structures changing and how does that kind of dynamic integration effect how the cell behaves as a whole?                                     And I think that that's one thing that we're really trying to do at the institute that is out of the scope that a lot of federally funded academic labs can do. A lot of times people are focusing on specific pathways or a specific molecule or a specific protein and don't necessarily have the bandwidth to look at the cell on a systems level. And so, kind of as Brock mentioned, with doing these different proteins as tagging the organelles we're hoping that being able to integrate that and generate enough data where that starts to become predictive I think can be really, really powerful. So... Brock Roberts:             Yeah, and there's another thing to add that's is kind of a larger thought that we are very preoccupied with and interested in, which is to take kind of a post genomic view of biology and cell biology in particular. Genomics has been so explosively successful in allowing us to document and document the state of cells at the level of which genes, which of the many, many, hundreds and thousands of genes are active in a particular cellular state, in a particular cell type or particular state that that cell's in.                                     We can easily get lists of genes that we know are functioning and turned on. What we want to do is take that to the next level and start defining a cellular state as a combination, a particular combination of dynamic behavior of those molecules which we can actually see. So we want to be able to see the parts work together. Not just have a list of the parts, and define states in that way. Kaytlyn Gerbin:           Yeah, and I think you kind of asked about what kinds of communities might find these tools useful and I think lot of the disease, we're thinking about how this might apply to disease modeling or drug screens or even developmental biology and kind of studying things like that, so I think a lot of our, we have some collaborations, and we've also been really trying to expand what kinds of groups and communities are using the cell lines.                                     There's been a lot of, kind of positive feedback on people taking, you know, a highly defined cell type that has a lot of QC done, and then having the right tools to be able to start to look at things like that. So, I think we kind of mentioned some of the tools we have, but I just to kind of restate that, all of the cell lines that we listed, along with many more, are available at Coriell.                                      And then, in addition to that you can get the plasmids that we've used, which have gone through also an extensive QC, so if people are working on patient derived, on their own patient derived IPS lines, you know, you could get the plasmids for whatever reporter and then put those in to your own cells. And we do have protocols available that describe our whole process in a lot of detail for how to do that and kind of different QC steps along the way. Brock Roberts:             Yeah, we describe each targeting experiment in enough detail for it to be, we hope, recapitulated in any human cell line or cell type without too much strain on behalf of the person that's doing that work. So we hope to kind of inspire people to try this, even if they might not be familiar with it. Kaytlyn Gerbin:           Yeah, and another thing is that our data is also available, so all of our imaging data that we're doing, and then, you can actually find that we have a website called the Allen Cell Explorer. And from there you can go through and look at all of the imaging, no, pretty much all of the images that have gone through our pipeline are now on the website. So you can go through and actually look at individual cells that were imaged during what, you know, as live cells, and then look at different structural tags that are in there.                                     Another thing that you can see on that is the predictive modeling, and so what we're able to start doing is predict the structure of, let's say, mitochondria based on the nuclear shape and another organelle that's in there. So, we're able to start doing a lot of that. So that, I think, will be really useful to people.                                     We going to add about the label free...? Brock Roberts:             Yeah, and some of the more interesting results that have emerged recently are, are the ability to infer through machine learning approaches and neural network approaches the status and state and sub-cellular localization of certain organelles in the cell and structures in the cell that are actually unlabeled. Those can be inferred from the sort of sophisticated analysis of bright field, you know, images that are not displaying any particularly obvious properties, any tags or anything like that.                                     But because the work has been done in the background to train these models and deep learning approaches with individual cell lines that do have these very specific reporters of distinct structures and organelles, because that data set exists, our modeling team and imaging team is able to appear actually quite deeply into the state of cells that are actually not labeled. Andrew Landstrom:     Wow. Brock Roberts:             So, it's pretty, pretty interesting. Kaytlyn Gerbin:           Yeah. Yeah, we don't have that up on our website yet, but that's in the works to get that actual predictive model. So essentially what that would mean then is that you could take a bright field image in your own lab and then put it into this model, and then get information about maybe where the nucleus is or where the mitochondria are or where the actin is predicted to be.                                     And all that is actually trained off of thousands and thousands of images that have come through the imaging and then the modeling pipeline. So, I think that that tool itself, once that is out and fully QCed I think could be, have a big impact right away. At least we're hoping that it will. Brock Roberts:             Hoping. And those computational algorithms are among the publicly available tools that we have that can be found through our website, and our publications that are coming out. Andrew Landstrom:     That's absolutely fascinating. Are you able to provide a specific example of how you've used, sort of, artificial intelligent, deep learning predictive modeling to infer a physiologic sale or response that was not directly observed? Brock Roberts:             Well, I think the response is, we're really hoping to go in that direction. To use this to, I guess, if you will, take shortcuts toward a response in the form of a state change after we alter the environment in some way, or perhaps alter the genome to mimic a disease, mutation, or something like that. Right now, we are building the relationships. So, we can, we know, and I guess one example we can give is progress through the cell cycle. Kaytlyn Gerbin:           Yep. Brock Roberts:             That would be one kind of clear example that we, we haven't done a lot yet to manipulate the cellular environment or trigger cells to go through different states, but obviously cells that are in culture and proliferating alter their state by progressing through cell cycle. So that's one example that we can detect. We can clearly look at how the morphology of cells and different cell cycle states that emerge that are their chromosomes are compacted or dispersed as they undergo synthesis or undergo division, progress through metaphase and so forth.                                     We can look at those cues and connect the state of the cell with respect to the cell cycle, to the state of some of the organelles, with the state of the mitochondria, for example. And we're hoping that same approach will hold up when we trigger, in some cases, more subtle changes to the physiology of cells. Andrew Landstrom:     That's particularly fascinating. I think the, you know, the ability to leverage that in the setting of, like you were mentioning, patient derived IPSCs from heritable diseases. You know, these sort of monogenic disease models that impart a biophysical defect in the cell could then be modeled and not only directly observed, but perhaps indirect cellular physiology might be inferred in a way that we really haven't been able to do so previously. Brock Roberts:             Absolutely. Yeah, there would be, in some cases there are monogenic disease mutations and pathologies that we know ought to have an effect, and we're really excited to see if that holds up, and how that holds up and what their phenotype is when looked at in this sophisticated way. And then there are other, more mysterious mutations that would be really excited to see a phenotype in. Kaytlyn Gerbin:           Our goal at the institute is to build the tools and provide the resources to the community to be asking these kinds of really detailed, very interesting questions. I mean, I think there's definitely interest in doing some of that work here, but our main focus is to design the tools and the methods and make that all available to the public as soon as it passes our QC. So, that's the, those are the kind of thing that I think the community will have a big impact on, testing these kinds of things in their own systems given you know, new tools and ways to do it, so. Andrew Landstrom:     Right. Brock Roberts:             Our whole, our whole ethos is to cooperate and to facilitate. And rather than compete with other investigators, we want to make things possible and that are shared and open. For example, our list of genes that we went with to target, that was on open collaboration. We asked as many specialists in the academic community as we could to develop a consensus of what would be the most useful markers for different organelles. And we chose those proteins and genes. So, we're really trying to be collaborators, as best as we can. Andrew Landstrom:     Are there specific examples of collaborations that you've felt were particularly productive or yielded some new exciting insight? Kaytlyn Gerbin:           Mm-hmm (affirmative), yeah. I could give you a few examples. So, Doctor Ben Freedman, who is at the University of Washington, he is working on kidney research. And so, he has a few of our cell lines, he actually, it's convenient because we are located right across the street from each other, so we'll see them fairly often, but, yeah. So, he works on kidney research with the different cell lines and he really wanted to get the cells into a 3D context. So, he is working on a lot of different tissue engineering to study developmented disease.                                     And so, he's also starting to make his own, their own mutations in the cell line, and so that's been, at least so far, that's been one collaboration that's I think has really been very powerful. And it's cool because we don't have the bandwidth right now to be looking at kidney organoids, but I think it's showed, kind of, the power of these kinds of cells and tools that, you know, when you have that you can do the live cell imaging with different structure within the same kind of organoid and you can get a lot of information, and so ... Andrew Landstrom:     Yeah. Kaytlyn Gerbin:           That, that's been fun to see develop. Another one that I know, Chris Chen at at Boston University is using our lines and is making cardiomyocytes with them as well and looking at the effects of patterning. And patterning is something that we also planning to do here, but that collaboration has been great to kind of get things going.                                     And we've also been working closely with a group at the University of Washington, Georg Seelig's lab, who's developed a new way of doing single cell RNA sequencing. And so, that's been fun, we've been looking at that with stem cells and then cardiomyocytes to, kind of help, help us figure out what the different states that the cells are in. And then that is going to help and form, kind of, what future tags we might do or when, when to do imaging or kind of what protivations we want to put the cells through. Andrew Landstrom:     That sounds like you're spanning the gamut really of downstream experimentation on these lines. Brock Roberts:             Yeah, and we've also had a lot of people buy the cell lines. Kaytlyn Gerbin:           Yeah. Brock Roberts:             Acquire them through the Coriell, we hope that each case of their productive application toward different research questions could be defined as a mini collaboration. Maybe we'll hear from some of these people. And in some cases we have, and there may be more things that spring out of that. Kaytlyn Gerbin:           Yeah, I think like, because the lines are available through Coriell it's, it's a little early to start seeing publications from the stuff, because we're a pretty new institute, but we do keep track of where the lines are going and, I mean it's exciting to see, I mean, pretty much all throughout the world there's people ordering the lines and starting to do research in a lot of different kinds of systems. Brock Roberts:             Right. Kaytlyn Gerbin:           So, we don't always necessarily directly collaborate with the people that are using the lines, but a lot of times we do hear from them or we'll run into people at conferences or something who have been using our lines. So that's really fun to see that its, our, you know, the work that we're doing here is actually producing things that people in the community are finding informative and useful. So, that's always fun. Brock Roberts:             It's still so early in this project. I mean we're just at the beginning of a lot of collaborative potential. So, we really hope to see this take off. Andrew Landstrom:     Yeah, and if people listening want to collaborate or want to learn more, how can they learn more and how can they get ahold of you all? Brock Roberts:             Oh, hold on, I think, first of all, we really want to funnel people to our website. We think it's a really great resource and at that allencell.org you can contact us through that link. We look forward to hearing from you. Kaytlyn Gerbin:           Yeah, so you can start with the website there. And as we mentioned before you can find all of our cell lines, plasmoids, protocols, etc. on this site. And we've also started to do a few more instructional videos, and so those are coming up on the website, too. So, some things, you know, especially as more groups are starting to use the lines, we do have the detailed protocols, but I think groups that maybe haven't done stem cell culture before or haven't worked with these kinds of IPS lines before, we're trying to provide as much content for people to make it easy for them to do the research. So we're starting to do more, sort of instructional videos. Brock Roberts:             Yeah, and we seek this out. We want to hear from people. It's not a bother. We're trying to get as much, we're trying to get the, we're trying to branch out and communicate as extensively as we can. Kaytlyn Gerbin:           Actually, one thing I just thought of that I want to add in her is that we have started to work with a few stem cell cores. And so, right now, I mean- Brock Roberts:             These are core facilities at universities. Kaytlyn Gerbin:           Yeah, stem cell core facilities at, yeah, exactly. So, part of trying to distribute the lines is that if we can, you know, individual investigators could get our lines from Coriell and get the licensing and everything to do that in their own lab, but it's, I think, going to be really great if we get some connections with the stem cell cores because then once we can provide the lines to them, they can distribute them to investigators that are part of the core.                                     And so, so far, we already have agreements in the works with University of Washington, UC Berkeley, and then the Salk Institute, but this is something that we're really hoping to expand this year. So I think, in particular, you know definitely contact us if there's questions about the lines or anything, but if you are part of a stem cell core at a university and you think that people at the university would be interested in using our lines we're working really hard to make, you know get, kind of, packages, protocol packages and everything available so that we can get these lines set up in the stem cell cores. Brock Roberts:             Right. Andrew Landstrom:     Well Brock and Kaytlyn, thank you so much for joining me. What an incredible resource that you all have created, and I especially appreciate how open and transparent you are with your lines and your quality control and how you just really, you know, try and strengthen collaborations and to start new ones. Brock Roberts:             Thank you very much for the conversation. Kaytlyn Gerbin:           Yeah, this has been fun, thank you. Jane Ferguson:             I hope you enjoyed listening to this episode of Getting Personal: Omics of the Heart. Let us know how we're doing by leaving a comment or tweeting at us at @circ_gen. We love to hear from you.   

Turn and give me a little baby smile as we model and pose for photographer Ann Landstrom here on the edge. Ann has a powerful testimony of what it looks like to start over through the lens of her camera. She is an extremely experienced photographer that uses her camera to change the way people look at themselves, both men and women. Hearing her story of passion, pleasures and  pain will keep the shutter open and let light come in. Her work spans from fashion to portraits, professional head shots and branding. And, we must mention her boudoir photos are simply illuminating.      

Jane Ferguson:                Hi, everyone. Welcome to Episode Four of Getting Personal: -Omics of the Heart." I'm Jane Ferguson, an assistant professor at Vanderbilt University Medical Center. This month, we have a special feature from early career member, Andrew Landstrom, who went to the Heart Rhythm Scientific Sessions in Chicago earlier this month and talked to some of the scientists who presented their research. So listen on for interviews Andrews conducted with Anneline te Riele, discussing the challenges and opportunities related to incidental findings in genetic testing, with Ernesto Fernandez, describing his research into whole exome sequencing and Long QT syndrome, and with David Tester, discussing novel variance and pathway analysis in Sudden Infant Death Syndrome. Andrew :                           My name is Andrew Landstrom and I am from the Baylor College of Medicine Department of Pediatrics' section on Cardiovascular Disease. I'm here at the 2017 Heart Rhythm Society Scientific Sessions. Anneline, will you tell us a little bit more about yourself, and what brought you to HRS? Anneline:                          Sure. So my name is Anneline Te Riele, I am a physician from The Netherlands. I finished my medical training in 2012 basically, in The Netherlands, and I started doing a PhD on ARVC in a combined project of our Netherlands patient as well as a group at Hopkins. So what brought me to HRS? I think of course the science. There's a lot of very good science. Actually, I think it's the best meeting for my purposes. Andrew :                           Absolutely. So will you just start by telling us a little bit about the spectrum of genetic testing in the clinic and about both the opportunities and the challenges that it brings? Anneline:                          Sure. So what we do in clinic, and I think this is really the challenge that we're facing currently, is we have moved from just testing on gene or one small panel of genes to bigger panels and then to whole exome or even whole genome sequencing. And I think the good part of that is that in certain cases, certain well-selected cases, you'll get a higher change of actually finding that gene that is responsible for disease.                                            On the contrary, it also leads to a lot of incidental findings. So findings that you were not expecting based on the phenotype of the patient and then you need to deal with those abnormalities that you've found and that brings on a lot of challenges as well for the family but also for us as physicians. Do we then need to screen those families, what do we do with this patient, do we treat them with medical therapies or drugs or do we give them ICDs? That kinds of question. So that I think is a virtually important part of what we're currently dealing with in clinical practice. Andrew :                           It does seem to be a very widespread problem. And here in the US of course we have the American College of Medical Genetics guidelines about reporting a variance. How do you think that that plays into the increased genetic uncertainty here in the US at least? Anneline:                          So that's a great questions. In 2013, the ACMG produced a guideline on which genes to report if you find these incidental findings. So 24 of these genes, and that's actually a big number, 24 of these genes are cardiovascular genes and that's mainly because changes in cardiovascular genes may detrimental effects down the line and really cause death or certain morbidities that are really important for the patient so we do need to deal with that.                                            And the problem with the ACMG guidelines and especially the pathogenicity guidelines is that they require two aspects. They basically require first that the variant was seen before in other cardiomyopathies or in this case other patients with disease. And that's really difficult for cardiomyopathy genes because these are large genes, they have a lot of novel or private mutations in there, so it's really hard to fulfill that requirement of having been seen before.                                            And the second thing is that the ACMG guidelines require functional studies as another proof of evidence of pathogenicity and of course, I think we would all like to do that in all of our patients, but it's just not feasible for financial purposes and all that. So that's a problem that we're facing. There are options and solutions but I think we'll talk about that later, but yeah, I think that's a problem that we're facing. Andrew :                           So on the one hand you have the ability to make a diagnostic decision based on a clear finding, but oftentimes the threshold to calling it a clearly pathologic variant is very high and oftentimes it never rises to that so it becomes more genetic uncertainty. Anneline:                          Yeah. I think that's basically right. And of course in an ideal world, we'll have certainty and say this is likely or this is definitely pathogenic, and this is likely or definitely benign, but in the real world, really, I think maybe even 80, 90% of the cases were in that gray zone in between and we need to deal with that. Andrew :                           Yeah, yeah. And you had some great resources that both scientists and clinicians alike can apply to these unknown, uncertain variants that might clarify things at least a little bit, and what are these tools? Anneline:                          So of course, from a traditional perspective, we have always looked at in silico predictive programs, we'll look at segregation data, and I think they're all very important, but they all have limitations, so for example, in silico predictive programs, they likely overcall mutations deleterious and segregation data is nothing more than evidence of pathogenicity of a locus to a disorder, not necessarily that variant, so the new things that are on the horizon, and a thing that could be the future of [inaudible 00:06:04] interpretation is collaborative project so really we should be collaborating, we should not be having our own little islands. The collaboration is the key here.                                            And collaborative efforts in the US have been for example, ClinVar and NHLBI funded effort, as well as ClinGen and ClinGen, or Clinical Genome, is perhaps the, at least it claims to be, the authoritative central resource to go back to that curates variants as being pathogenic yes or no. And I think these databases, ClinVar finally has a database entry, so the variants will be in ClinVar, but ClinGen provides an expert panel of individuals who will curate these variants as being pathogenic yes or no. I think that is a central resource that we should all be aware of. I know these are not the only ones, there are other collaborative efforts out there.                                            I mean, there are ways to connect clinicians, so for example, Match Maker Exchange is a website that you could use to enter your variant and the phenotype of the patient and you submit your own information and then you'll get matches in other databases, but not only your own match shows up. So if, say, two years later, another physician comes up and looks for the same variant, you'll get a pop up, which will actually be very nice for these clinicians to get in touch. So that's, I think, the feature ... future of variant interpretation is collaboration. That's basically my, I think my main important message here. Andrew :                           I think that's absolutely right. I think this has become sort of a big data question that requires many perspectives, and a lot of resources to be able to curate accurately. What are some of the limitations of these tools that you've seen that kind of, you have to keep in mind in terms of trying to determine whether a variant is truly pathologic or not with a patient that you have sitting in front of you? Anneline:                          So that is, I mean, of course, there's many limitations in the things that we currently do because there's so much that we don't know. But for example, to give you an example, ClinVar I think, is one central resource that we should all be aware of and if you go to ClinVar, there is actually data from two years ago, and I'm sure the numbers are high if we would look now, but if we look in ClinVar two years ago, we already saw that of the, say 120,000 variants that were in the database, 21% of these variants were called VUSes but if you look at these variants, 17% of the cases, the labs or the individual submitters of ClinVar didn't agree on the actual classification of that variant.                                            So the limitations that we all should be aware of is that there is not one single solution and you should look for evidence and really research your variants. So look at Popmap, look at what is out there, look the patient of course, look at the clinical phenotype, does it match what you think the gene should be doing or not, or is it completely unrelated? And then of course search these databases but be aware of the fact that there may be errors there.                                            Another thing I want to highlight too is that we typically go to population databases, so Exome Variant Server, ExAC, I think these are very popular databases that we use to look at the frequency of variants in a selected population. But really these databases may have sub-clinical disease patients, so I know ExAC has three NYBPC-3 mutations that are known to cause HCM, so this is something to keep in mind. There's not a gold standard truth if you open these databases, but you should have multiple pieces of information when interpreting your variant. Andrew :                           And that's a good point. I think with a lot of these cardiomyopathies and channelopathies, particularly some of the more frequent ones, when you have a database of 60,000 people, at least a couple of them are going to have disease. Anneline:                          Yeah. I think that is part of the problem. I mean HCM is pretty prevalent, I mean one in 500 individuals likely, I mean these are recent numbers, has the disease. So I think the cutoff of a minor allele frequency of five percent, which is in the ACMG guidelines, I think is way too high for this disease. So this is what the cardiovascular expert panel of ClinGen has done, so they ... This is, ClinGen, as you might know, Clinical Genome, is a one-on-one team of curators that know the framework of ClinGen and then there is disease experts that are very well accustomed with the disease and the genes associated with it. So they provide teams and these teams work together, and the cardiovascular expert group has recently published a modified, or customized, ACMG guidelines on how to deal with the intricacies of the cardiomyopathies and for example, NYH-7 which is the first genotype deposed in ClinGen or in ClinVar finally.                                            So they modify that cutoff, the minor allele frequency of five percent, which is the BA-1 ACMG guideline cutoff, they changed that to 0.1% and I think that's exactly what you were saying, that is important to keep in mind, some of the cardiomyopathies are way more prevalent so you should not consider that if you see it in a population database that you think that it's, then it's normal, it's not necessarily the case because this is a prevalent disease. Andrew :                           Yeah, and particularly when commercial genetic testing companies all can't agree that a variant is bad, and we all can't agree that a healthy variant may or may not be good, there is definitely a lot of genetic uncertainty there. Anneline:                          Exactly, exactly. Andrew :                           Now, whole-exome sequencing certainly has its role clinically, even with that genetic uncertainty that we spoke about, but it has a clear role in genetic discovery as well. Anneline:                          Sure. Andrew :                           And you were part of a very recent paper, and you led a very long list of authors, speaking more about your collaborative approach to genetics research that evaluated a novel substrate for ARVC, is that correct? Anneline:                          Yes. So this is something I'm actually pretty proud of. As you said, it's a collaborative effort, so it literally take a village to do these kind of studies and we're lucky enough to collaborate with a lot of people who are interested in the same topic. So what we did ... and I metnioned to you in the beginning, I come from the ARVC field ... So what we did is we had one ARVC patient that was discovered by whole-exome sequencing to carry an SCN5A variant and we, in and of itself, found that that was very interesting, because SCN5A, as you know, has been associated with Brugada syndrome predominantly but many other cardiomyopathies as well, so DCM, even ACM. There's been a lot of controversy about SCN5A in that matter.                                            So the computational data, the population data, it all pointed to the fact that this variant may be pathogenic, but we weren't really able to connect those dots just yet. So we then collaborated with the group in NYU with Mario Delmar, who did, first of all, functional studies on the sodium channel, but what was nice is that he was able to use his novel method of super-resolution microscopy which is a way in which we can look at the nano-scale structure of the cardiomyocytes, or really the small, small levels of molecules that you see in these cells. And what we did is we found that not only NAV1.5 which is the gene product of SCN5A but also [inaudible 00:13:53] which is an adherence structure molecule, which links the cells together was actually less present in our ARVC patient compared to the control. And this was in the IPS so cardiomyocyte molecule, which we corrected using CRISPR-Cas9 technology so I think at least in current practice, on of the best pieces of evidence that we can get.                                            So I think this shows that our SCN5A variant, I mean, in this case, probably really was pathogenic, but also in a pathophysiological standpoint, explains to us how SCN5A mutations, which are typically thought to be only affecting the sodium channel, can also lead to cardiomyopathy phenotype which has implications beyond the ARVC world, but also in DCM I think this is a nice finding of collaboration that I think ... I hope more people will look into this. Andrew :                           Absolutely I think the trouble with SCN5A is exactly like you were saying, it's been implicated in Long QT, Brugada Syndrome, SIDS, [inaudible 00:14:57], now ARVC, and even nodal disease, like sinus syndrome and things like that. So the ability to show sort of mechanistically, that while you have a change in your sodium channel gating that you also have a change in the way that the cells can connect with each other and form contractile force is, I guess, key to your study. Anneline:                          Yeah, yeah. I think this really, I mean, I'm hoping at least, it was also finally published in a journal that looks more into functional studies, so not necessarily only genetics, and I think we need to work closely not only on the genetic side, but look closely at the pathophysiological standpoint for gene discovery purposes because this will really explain to us why one gene is implicated in one disease, and also it points to possible directions to perhaps stop the disease process and treat these patients, which I think is vital in our clinical practice. Andrew :                           So are SCN5A mutations in ARVC a common finding or are they rare? Anneline:                          So they are pretty rare. I mean, we do find them every now and then and maybe they're modifiers. So what we did to follow up on that one individual, we check 281 ARVD patients who were screened just by regular screening, not by whole-exome but we did a targeted screening of SCN5A and we found five variants in these 281 patients, so that's two percent. I mean, it's still rare, but it is as rare as any other minor gene causing ARVC, but it is a rare feature, so I mean, I think it could be a player. And interestingly, the phenotype didn't change much. It wasn't really different from the ARVC patients without an SCN5A mutation which is reassuring.                                            What we also saw is that the prevalence of mutations in those with desmosomal mutations. So ARVC is, as you know, typically associated with diseases or mutations in the desmosome. It was more often seen in those without a desmosomal mutation. That was almost double as frequent as in those with a desmosomal mutation. So it does give us some direction to the fact that this may be a player out there. I mean of course it's not Plakophilin-2 which is the major player, I think, in ARVC, but I think it may cause a, at least a certain form of cardiomyopathy of arrhythmogenic cardiomyopathy that we need to be aware of. Andrew :                           And how do you think your new discovery of SCN5A being associated with ARVC, how do you think that plays into the bigger discussion we were having about expansive genetic testing and what that may mean for a patient as far as diagnostic utility but also limitations of variant interpretation? Anneline:                          That's a great question. So I think we should be cautious of saying this gene causes only this disease, and I think this is a common feature not only in ARVC but in a lot of cardiomyopathies and even in channelopathies. I think the concept of one gene causes one disease is outdated. We know that multiple genes have multiple effects and this SCN5A, of course the gene product is NAV1.5 which is the major alpha subunit of the sodium channels so it is really not the canonical function of SCN5A or NAV1.5 that causes cardiomyopathy here but it's a non-canonical function so I think we should be aware of the fact that gene products have different functions and that there can be overlap of the cardiomyopathies. So of course I think we should be screwing SCN5A in our ARVC patients and I'm hoping a lot of labs and a lot of physicians are already doing that, but it's really not the only thing that is associated with ARVC. So that's important to keep in mind. Andrew :                           What do you think the next steps are for sort of broadening the implication of your finding? Anneline:                          So what we are doing currently, and is a little bit of a sneak peek, because this data is not really out there yet, but we have, in this cohort, we found these five variants in 281 individuals, and we're currently working on one of these individuals to get another IPSO cardiomyocyte cell line and look into the functional components to that. And interestingly, this variant, that exact variant in that ARVC patient was also found in a Brugada Syndrome patient. So wouldn't it be nice to actually set them side by side and see what the differences are?                                            Of course this is a little bit of a future music, if you know what I'm saying, like this is something that we don't have just yet, but I think what we need to figure out is how epigenetic or environmental factors play into this field and to explain how one gene or one variant, even, can cause opposite functional effects in different phenotypes. Andrew :                           What do you think is needed to help clarify some of the genetic uncertainty you see clinically? Anneline:                          I think a lot of collaboration, a lot of money, quite frankly. I think we need to ... I mean, the functional data is really helping us not only for understanding that single variant, but also for gene discovery, and as I said, for treatment down the line, that is necessary, and I think the variant of uncertain significance, I mean, if we all live on our little islands and only do our little practices, then we're not going to go a lot further. So we need to work together to understand what your patient has in this variant, my patient had in that variant, and this is our phenotype, so we need to connect those dots to be able to make certain conclusions. Andrew :                           Well, I'm all for collaboration, as well as additional money, that's good. Anneline:                          Good. Andrew :                           Well, thank you so much for spending time with us. Anneline:                          Sure. Andrew :                           And again, congratulations on a wonderful presentation. Anneline:                          Thank you very much. Andrew :                           I'm joined by Dr. Ernesto Fernandez from the Baylor College of Medicine to talk about his research project. Ernesto, I'm wondering if we can just start by introducing yourself and what your project is. Ernesto:                            I am a second-year pediatric resident, I'm applying to a cardiology fellowship right now and I'm interested in, obviously, all aspects of pediatric cardiology. We're trying to figure out whether testing for Long QT genes or Long QT syndrome is actually warranted in otherwise healthy individuals. We're trying to see what the yield is on these testings, specifically whole-exome sequencing. Andrew :                           And I think this project really hits on an important point, whereby, because we've been able to interrogate the genome more comprehensively with clinical testing, that we've run into more incidentally identified variants. And these variants can pop up in genes, like the genes responsible for Long QT syndrome. Talk a little bit more about these variants, what the implication is of finding these variants incidentally, and what your project hoped to target as far as the diagnostic value of these variants. Ernesto:                            Yeah. So I guess the answer to your first question is that we are coming up with these marvelous new techniques of analyzing the genome and now we're using whole-exome sequence testing to look up is someone has any exome that's abnormal and this has caused a huge problem whereby we're now finding all these variants that we don't really know what they mean. We call them variants of undetermined significance.                                            Our study is basically premised by the fact that if you have no underlying suspicion for any arrhythmic disease, there's really no need or no indication to be referred for whole-exome sequencing testing, given that the most likely result is a variant that we don't really know what it means. And it's probably going to be benign. Andrew :                           So on the one hand, you have a well-established gene panel that's being used for diagnostic purposes with you index of suspicion being high for Long QT syndrome versus something like a whole-exome gene screen where somebody may not be thinking about Long QT syndrome as a diagnosis and have low pre-test suspicion but then comes back with a variant found in these genes sort of incidentally. Is that sort of the dichotomy you're drawing? Ernesto:                            Yeah. I think the best way of explaining it is through Bay's Theorem whereby if you have someone with a high index of suspicion when you start off to have sudden cardiac death, a family history of an arrhythmic disease, and you get a test for it, such as a gene panel for Long QT syndrome, and they come up with a positive test result, then you're going to say, "Oh. I should probably evaluate this further," whereas if you have someone who has some dysmorphism, they have delay, they might have seizures, but there's no family history of sudden cardiac death, no personal history of syncope, then there's really no need to send off this big gun, the whole-exome sequence, because you're likely to either get a normal variant or you're likely to get a variant that we don't know what to make of. Andrew :                           So I think, Ernesto, that nicely summarizes the clinical question that you had in mind. What was your hypothesis going into the study, and how did you seek to approach that hypothesis, sort of experimentally? Ernesto:                            So we came up with the hypothesis that if you have an incidentally identified variant within the whole-exome sequencing tests without any other clinical suspicion, it's likely to represent a benign finding. We went about by analyzing the data from the Baylor Miraca labs on the whole-exome sequencing data that they achieved, and we looked specifically at individuals who had gotten these tests and found to have a variant of undetermined significance, or had a pathologic variant for either one or all 17 of the genes for Long QT syndrome. We compared them to individuals who had known Long QT syndrome that had undergone genotype testing, and we [inaudible 00:25:21] these individuals from the literature. And we wanted to compare the whole-exome sequencing cohort to individuals who were otherwise healthy and had obtained a whole-exome sequence. So these are patients or individuals from the well-established ExAC database that are believed to be ostensibly healthy individuals. Andrew :                           So if I understand you correctly, you're comparing this unknown cohort, that being the rare variants found in whole-exome sequencing, against a positive control cohort of pathologic cases versus a negative control cohort of healthy individuals derived from the ExAC database to look for whether those west variants are more similar to the cases or the controls. With regards to the west cohort, what was the prevalence of individuals with these incidentally identified variants, how many did you find? Ernesto:                            So we actually found just about 49% of individuals had some variant in Long QT syndrome gene, and noted that about 12% of them had a mutation in the major causes of Long QT syndrome, and just over a third, or 36% had a mutation in the more rare causes of long QT syndrome. Andrew :                           That's a pretty surprising finding. So you're saying that one in two individuals who get whole-exome sequencing sent for whatever reason, have a variant in a Long QT-associated gene? Ernesto:                            That's what the data suggests. Andrew :                           And where did you go from here? Ernesto:                            So from there, we went onto compare the variant frequency between the case's cohort, those individuals with known Long QT syndrome, those individuals in our west cohort from the Baylor Miraca labs, and those individuals from the ExAC database who are otherwise healthy. So we noted that in our west cohort, there was about 13% of individuals who had a positive variant in the Long QT syndrome one through three genes, the major causes of Long QT syndrome. When we compare that to the ostensibly healthy individuals from the ExAC database, it was 12% in that study that had some variant in Long QT syndrome genes that are major causes of Long QT syndrome itself.                                            This was statistically similar, it was indistinguishable. And then when we compared it to the pathologic cases, it was actually about 50% of those cases who had a positive variant in a Long QT syndrome gene one through three. Andrew :                           So there was a relatively low frequency of individuals who had variants in one of the big three Long QT genes in both controls and the west cohort, and was obviously much higher among individuals with a diagnosis of Long QT syndrome. Ernesto:                            Yep. That's exactly what we found. Andrew :                           And where did you go from here? Ernesto:                            And then from there, we had a good idea that there was probably a big difference between cases and west, but we wanted to make sure, gene by gene, that there was no difference between our west cases and the ExAC database, the control cases. So we mapped each variant frequency by gene for the major causes of Long QT syndrome. There was no statistically significant difference between the west and the controls. Andrew :                           So the gene frequencies between the controls and the west were indistinguishable and very much different, both of them, it would seem, to the pathologic cases. Ernesto:                            Correct. Andrew :                           And you then looked at the position of these variants, the actual amino acid residues, correct? Ernesto:                            Yeah. So we looked at, for KCNQ1, KCNH2, and SCM5A, the three major causes of Long QT syndrome, one, two, three respectively, and we mapped out the amino acid positions where there was actually a mutation for each individuals. So the cases, controls, and pathologic cohorts. We determined the percent overlap between the west cohort and the controls and the percent overlap between the west cohort and the cases and noticed that for all three, there is a huge preference for west and control versus west and cases. Andrew :                           So if you're a west variant you're more likely to reside in the residue also occupied by a healthy individual variant as opposed to a pathologic variant? Ernesto:                            Yeah. Exactly. Andrew :                           And so what did you do next? You retrospectively looked at some of the charts of the patients who were seen at Texas Children's Hospital, correct? Ernesto:                            Mm-hmm (affirmative). So then we had 223 total individuals that had an incidentally identified variant within one of the major three genes, the Long QT syndrome genes. We looked at the reasons for their referrals and noticed that the vast majority of individuals were referred for some developmental delay, for some dysmorphism, for a non-cardiac cause, and then it was only about 23% of these individuals that actually had a reason for referral that was cardiac in nature. And less than on percent of individuals were referred for a solely cardiovascular reason. And we concluded that it's unlikely that these individuals were referred for a cardiac reason, as the data suggests, and that as a result, the index of suspicion for an arrhythmia is likely lower in these individuals. Andrew :                           And what did you find when you looked at the charts of those individuals? Ernesto:                            We had EKG data for a good number of them, and we excluded individuals who obviously had no EKG data, and we excluded individuals who had some congenital abnormality and then anyone with any other arrhythmia that would make the QTC interpretation more difficult, such as interventricular conduction defects.                                            We ended up with 62 individuals and 61 of them had a normal QTC, so there was no evidence of QT prolongation at all. There was one individual who was left who had borderline elevated QTC of 460, which was our cutoff for borderline elevation and this individual had actually been seen by pediatric cardiology at Texas Children's Hospital and found to have ... a history of syncope and it was found to be non-cardiogenic in nature. Andrew :                           So matching the variant data which suggested that you had likely found background variation in the west, you found no evidence of Long QT syndrome in these individuals who had variants in Long QT genes. Ernesto:                            That's correct. So, the overall percent was very similar between the healthy individuals and the west individuals. The variant frequencies were almost indistinguishable, and then the variant co-mapping for all, for both the west and the controls, was preferential to the western cases. So that kind of matched what we found in our study, that there was no clinical suspicion or clinical diagnosis of Long QT syndrome in these individuals who had been found incidentally. Andrew :                           Well that sounds to me to be a pretty big finding. Ernesto:                            Yeah. I think it's pretty important to get this information out there. Andrew :                           So what do you think the take home message for your study is? Ernesto:                            I think the take home message is if you don't have a suspicion of Long QT syndrome or of an arrhythmia, there's low likelihood that such a big gun test as the whole-exome sequence is likely going to change your mind. Andrew :                           So Ernesto, what would you advise a cardiologist who maybe gets a patient in clinic with a chief complaint of a VUS in a Long QT associated gene picked up on west, what would you advise based on your study findings? Ernesto:                            They're going to have to determine their own pre-test suspicion. They're going to have to get a good history and physical, probably get a baseline EKG to determine what the QTC intervals are, and if there's really no other clinical suspicion for Long QT syndrome, they're likely to be able to provide reassurance at that point in time. Andrew :                           Ernesto, what do you think the next steps are for this project, and what do you think still needs to be done in the field to reinforce your conclusions? Ernesto:                            I think my study is one of the early studies of this field, so getting more studies like this and other channelopathies, getting not just looking at Long QT one through three but looking at all of them, and in patients who've been evaluated at Texas Children's or any other institution would be helpful. And then moving forward to give more credence to the idea that if you have history that's reassuring and physical exam that's reassuring, then you probably don't need to have further testing. Andrew :                           What do you recommend if your index of suspicion is high for Long QT syndrome, so maybe a QTC in the low 480s, maybe a family history of syncope or seizures, do you think whole-exome sequencing is the way to go? Ernesto:                            Right now, that's probably not the best test, given all these incidental findings that we don't really know what to do with. There's other tests that are more high-tailored for those specific diseases, like Long QT syndrome panel among others, that are probably more likely to give you a positive post-test probability. Andrew :                           So testing for the disease you're suspicious for as opposed to testing indiscriminately? Ernesto:                            Yeah. Andrew :                           So Ernesto, thank you so much for taking the time our of your day to speak with us. Ernesto:                            Thank you, Andrew. Andrew :                           I'm here with David Tester, senior research technologist working with Mike Ackerman at Mayo Clinic, and he just gave a wonderful talk on whole-exome sequencing and next-generation sequencing as an unbiased look to determine underlying causes of Sudden Infant Death Syndrome, or SIDS. So David, I'm wondering if you can introduce yourself and talk a little bit about your project. Dave:                                 Sure. I'm Dave Tester and I'm at the Mayo Clinic, again with Mike Ackerman. Dr. Ackerman and I have been together for about 18 years now, with a real focus on genetics of sudden cardiac death disorders. So this latest study was looking at whole-exome sequencing in a population of SIDS cases in collaboration with Dr. Elijah Behr at St. George's University in London.                                            And really the approach, what we were aiming for is really kind of two-fold. First we were looking to determine what is the yield of ultra-rare variance within genes that have been implicated in cardiovascular disorders? These would be the cardiac channelopathies and some of the cardiomyopathies such as ACM or ARVC, for example.                                            And the second thing that we were wanting to look at was can we use this to search for sort of novel candidate genes for Sudden Infant Death Syndrome susceptibility? And so we took that aim and really the main result was to show that about 14% of our SIDS cases had what we term potentially informative variants. And those are going to be variants that were within sort of the major channelopathy genes that are implicated in Long QT syndrome or CPVT as well as loss of function variants within the 90 ICC genes that we had examined.                                            Using the ACMG guidelines for determining the pathogenicity of variants, about 4.3% of our SIDS cases hosted an ACMG guideline predicated likely pathogenic to pathogenic variant. And most of those variants represent either a frame shift or splice site error variance really in minor cardiomyopathy genes and channelopathy genes. So there's still a lot of work that needs to be done in terms of looking at specifically missense variance within channel genes and that sort of thing, and really kind of functionally characterizing those to determine whether or not they truly are pathogenic or if they should remain variants of uncertain significance. Andrew :                           And so you took a very complex disease like SIDS with probably a number of differens ideologies and found a pretty good percentage have suspicious variants, that 14% or so, and then 4% had variants that were so suspicious they would meet American College of Medical Genetics guidelines for being a possible or likely pathologic variant. Where do you think this study lies in sort of the continuum of identifying the genetic ideology of SIDS, and what do you think these findings sort of add to that overall picture? Dave:                                 Well I think these findings in general really just kind of show the complexity of SIDS. Whether or not SIDS is really truly genetic or not, or perhaps it just, if it's not monogenic, perhaps it's polygenic, and so those are some things that we should be considering and looking at. Now some of those questions might be able to be answer through our whole-exome sequencing data set that we have, and I think those are really going to be kind of the next phases.                                            We can also take and do some pathway analyses of the exome sequencing data, for example, and see our variance kind of lining up on certain pathways that may contribute to certain pathologies that could contribute to SIDS. Andrew :                           And in your study, you had a few genes where the number of variants that were found in SIDS cases were higher than in your controls. Can you speak some more about what those genes may tell you in the context of pathway analysis for SIDS? Dave:                                 Yes. So there was ... There were not genes that came out with sort of a genome-wide significance level. But there were at least 400 genes that had a p-value of 0.05 over representation in SIDS versus our ethnic match controls and 17 of those genes have a p-value of 0.005 and we're really kind of focused on some of those that have a little bit higher p-value for us to assess. A few of those genes may represent biologically plausible candidate genes for SIDS and we were kind of actually going through and considering which ones we'd like to follow up on in terms of function. Some of these genes do play a role in, say, cardiorespiratory system and function of the heart as well as in the brain. Andrew :                           So then given all these findings, and the fact that you may have some candidate genes and candidate pathways that might be interesting to look at further, what are the next steps that you think would help this project move forward, and what do you think the field of Sudden Infant Death Syndrome and Sudden Unexplained Death Syndrome needs to kind of move forward? Dave:                                 Well I think from a genetic standpoint, the study that we just complete was really on a large set of unrelated infants that had died suddenly. We did not have access to parental DNA and so moving forward in terms of the genetics, I think incorporating sort of a trio analysis I think would get at the question of sort of [inaudible 00:42:01] variance for example. The other things, in terms of genetic standpoint is perhaps looking at different genetic mechanisms. Whether these are copy number variance that may be missed by exome sequencing, perhaps some of the SIDS could be due to epigenetic abnormalities or even small chromosomal abnormalities that perhaps may not be detected on certain arrays on there being used. So I think going forward, kind of taking those approaches to look for sort of unique genetic variation. Andrew :                           Well Dave, thank you so much for taking the time to speak with me and congratulations on a great project. Dave:                                 All right, great, thank you. Jane Ferguson:  Thanks to Andrew for highlighting the interesting precision medicine research presented at HRS and thanks to you all for listening. We'll be back with more next month.

Hi, wir sind ja nun seit ein paar Tagen mit dem Wohnmobil unterwegs. Derzeit sind wir in "Camaret-sur-Mer" und das Akkuproblem hält uns weiterhin etwas im Griff. Ist es mit dem Miet-WoMo doch tatsächlich eine kleine Herausforderung alle Akkus aufgeladen zu halten. Einfach weil beim stehen ohne Landstrom keine 230V zur Verfügung stehen und alle unsere Ladegeräte auf 230V ausgelegt sind. Deshalb wie angekündigt, etwas kürzerere Blogbeiträge   Hier ein paar erste Tipps die wir zukünftigen Miet-WoMo Fahrer mit auf den Weg geben können: Handy, Smartphone, Tablett, mobilen Router aufladen Hier bietet es sich an unbedingt so einen 12Volt auf USB Adapter für den Zigarettenanzünder anzuschaffen. Wir haben nämlich zwei 12Volt Dosen, aber keinen Adapter um unsere USB Geräte daran aufzuladen. Somit werden wir die Tage im Supermarkt schauen ob wir dort so einen Adapter bekommen. Diesen hier würde ich mir zu Hause direkt bestellen:     Und ich würde mir eine Powerbank zulegen. Denn das war ich kurz vor Antritt des Urlaubs auch ncoh am überlegen, habe mir dann aber gedacht "ach komm, Strom haste ja eh immer dabei"....Tja schon, aber irgendwie nicht so passen. Diese Powerbank hatte ich ins Auge gefasst und werde ich mir danach auch gleich zulegen:     Kaffee kochen Da uns keine 230V zur Verfügung stehen kann man auch nicht wie gewohnt den Kaffee durch die elektrische Maschine jagen. denn die läuft ja mit 230V, die wir nicht haben. Da wir aber so eine ganz einfache Filterkaffee Maschine haben, haben wir natürlich Glück. Also gehen wir nun hin und kochen das Wasser auf dem Gasherd auf und schütten ihn dann in den mit Kaffee gefüllten Filter und das ganze läuft dann direkt - wie gewohnt- in die Thermoskanne. Problem gelöst. Wer also damit liebäugelt seine SENSEO oder so mit zu nehmen sollte vorher Fragen wie und ob das irgendwie geht im Miet-WoMo.   Staubsauger Die wohl beste Anschaffung. Ganz egal ob Wohnmobil oder Wohnwagen. Diese kleinen und handlichen Dinger sind sozusagen Gold wert. Einfach in die Hand nehmen und über den "Dreck" rollern und weg ist das Zeug. Ideal für die Sitzgruppe oder auch das Bett. Denn wer am Starnd unterwegs ist schleppt den Sand ja überall mit hin. Und mit diesen handlichen Dingern ist das Problem, völlig stromlos, direkt gelöst. Hier der Link zu den Handstaubsaugern:   So das war ins aller kürze an Tipps. in der Podcastfolge selbst ist es natürlich nicht ganz so knapp gehalten. Aber der liebe Akku. :-) LG Dominic

Sebastian ist 23 Jahre alt und mit Leib und Seele Segler. Mittlerweile ist er sogar mit seinem Hausstand auf sein 22-Fuß-Schiff Bea Orca umezogen! Er erzählt von seiner Reise auf dem Schlau-Segelboot durch Friesland, sein Buch und sein neues Abenteuer mit BEA, seiner Leisure 22. Sebastian Janotta privat: Ich bin 23 Jahre alt - und mit Leib und Seele Segler. Nach zwei umzügen fürs Segeln - erst nach München (was mich da geritten hat...) und dann schließlich nach Cuxhaven, an die Nordsee - bin ich jetzt endlich auch auf mein 22 Fuß Segelboot gezogen. Neben meiner Vollzeitstelle in einem chemischen Labor verbringe ich sehr viel Zeit damit meinen Blog www.seglen-ist-leben.de zu betreiben. Wie bist Du zum Segeln gekommen? Angefangen mit dem Segeln habe ich 2012 während meiner Ausbildung. Damals kam ich gerade ins vierte Lehrjahr und wollte endlich malwieder im Urlaub was unternehmen. Durch einen Tipp meiner Eltern wurde ich auf die DJH-Segelschule in Bad Zwischenahn aufmerksam, bei der ich nicht nur einen schönen Urlaub mit Gleichaltrigen verbringen konnte, sondern auch noch den SBF Binnen machte - und mich mit dem Segelvirus infizierte. Charterst Du? Irgendwie ist es bei mir nie wirklich dazu gekommen. Abgesehen von ein paar gemiteten Jollen auf Seen in Bayern habe ich nie gechartert. Nach einem Jahr in München ging es zurück nach Rheinland-Pfalz, wo ich mir bald mein erstes Boot - BEA, ein 8 Fuß Schlauchsegelboot - kaufte. Mit ihr ging es nicht nur auf nahe Baggerseen sondern auch für mehrere Törns nach Friesland, woraus neben meinem Blog auch mein Buch "Schnell kann Jeder", erschienen beim millemari.-Verlag entstanden ist. Möchtest Du Dir ein eigenes Schiff kaufen oder hast Du vielleicht bereits eins? Mittlerweile bin ich bei meinem zweiten Boot. Nach meinem Umzug aus dem Binnenland an die Nordsee war klar, das ich etwas neues Brauche. BEA, so toll sie auch ist, war einfach für die Nordsee denkbar ungeeignet. Nach einiger Suche habe ich mich schließlich für eine Leisure 22 entschieden. Nach zwei Urlaubs- und ein paar Wochenendttörns im Sommer und Herbst 2016 bin ich im Januar 2017 dann auch Vollzeit aufs Boot gezogen. Sie ist somit mittlerweile im wahrsten Sinne des Wortes mein Zuhause. Hast Du ein Traum-Schiff? Ganz ehrlich? Aktuell bin ich mit meiner Leisure 22 absolut zufrieden und will gar kein anderes Boot. Selbst wenn das Geld da wäre - ich würde es lieber nutzem zum Segeln. Wenn ich mich aber nach einem größeren Boot umsehen würde wäre entweder ein langes Plattbodenschiff mit wenig Tiefgang oder, fast noch lieber, eine Ovni 28 ein heißer kandidat. Aber wie gesagt: Ich bin noch immer absolut begeistert von der Leisure 22 und plane aktuell keinen Törn, den ich ihr nicht zutraue. Da ist er der Skipper das thema.... Welches Revier befährst Du im Moment am liebsten? Ich mag raue Reviere, Orte die nach Abenteuer riechen. Somit fühle ich mich auf der Nordsee sehr wohl. Wenn Geld keine Rolle spielte, wie sähe Deine seglerische Zukunft aus? Schwierig. Wenn Geld keine Rolle spielen würde? Ich nehme an ich würde - ganz langsam - Nordeuropa besegeln. Ostsee, Nordsee, Nordatlantik und hoch nach Nordnorwegen bis ins Nordpolarmeer. Anfangen würde ich aber aktuell ganz klar - im Wattenmeer. Welches ist Dein Lieblings Gegenstand am Boot oder welches Teil magst Du besonders und warum? Das hängt immer ganz von ab. Im Moment ist mir tatsächlich meine kleine Heizung am wichtigsten. Im Winter ist sie vielleicht das elementare Ausrüstungsstück. Für mal eine Woche ohne mag dies auch ohne gehen - ich habe ja bei Temperaturen um den Gefrierpunkt schon bei meinem Wintertörn mit BEA draußen gezeltet - aber wenn man an Bord lebt sollte ein wenig Komfort doch sein. Dies ist einer der Gründe, weshalb ich mir noch eine zweite Heizung (allerdings eine, die vom Landstrom unabhängig ist) kaufen mag. Unterwegs.... Das Ankergeschirr. Auch hier wird dieses Jahr nachgerüstet (aus Gründen!). Ankern ist für mich etwas ganz besonderes, hat es geschafft innerhalb kürzester Zeit zu einem ganz wichtigen Bestanteil des Segelns für mich zu werden.So ein Ankergeschirr eröffnet einfach ganz neue Möglichkeiten. Zudem gehört es für mich mittlerweile auch zur Sicherheitsausstattung. Meine Segelabenteuer mit BEA Mein erstes richtiges Segelabenteuer waren meine Törns mit BEA, meinem 8 Fuß Schlauchsegelboot - ein Boot, das eher für ein paar Stunden auf einem Baggersee gebaut war denn für längere Törns wie ich sie mit ihr unternahm. Während dieser Törns wurde mir recht schnell klar, das ich mehr Meer will. 2016 zog ich daher an die Nordsee und kaufte mir, nach einer längeren Suche, Bea Orca. Nach einer Testphase 2016 kam sie ende Oktober aus dem Wasser und ins Winterlager, wo ich einige Anpassungen vornahm. Am 16.01.2017 ging es dann  für sie wieder ins Wasser - und für mich an Bord. Seit diesem Tag wohne ich auf ihr. Mittlerweile habe ich (für ab diesem Tag) auch meinen offiziellen Wohnsitz an Bord. Die Wohnung ist gekündigt und wird gerade aufgelöst. Welche Buchempfehlung kannst Du unseren Hörern mitgeben? Natürlich zunächst einmal mein eigenes Buch - "Schnell kann Jeder" von mir, Sebastian Janotta. Hier berichte ich von meinen Abenteuern im 8 Fuß Schlauchsegelboot. Ich war, als der Verlag auf mich zukam selbst erstmal skeptisch. Immerhin bin ich weder Segelprofi noch Langfahrtsegler! Doch jetzt, wo ich das Ergebniss kenne kann ich es begeistert empfehlen. Ein weiteres Buch ist "Mein Boot ist mein Zuhause" von Holger Peterson, erschienen ebenfalls beim millemari.-Verlag. Sowohl Inspiration als auch Information für mein Leben an Bord habe ich reichlich von Holger und aus seinem Buch bezogen. Und auch Merle Ibachs "Ostseeprinzessin" fand ich ganz toll. Unter www.gluexpiraten.de/audiobooks bekommst Du fast alle Titel als Gratis-Hörbuch im kostenlosen Probeabo. Gleich hier ausprobieren! Welchen Fehler hast Du mal auf oder an dem Schiff gemacht und was war die wichtigste Lektion daraus? Ein Fehler? Schwierig... Wobei: Selbstüberschätzung und Selbstbetrug. Beim aller erster Seetörn ging einhand von Hooksiel nach Cuxhaven. Und endete damit, das mich die Seenotretter die letzten Meter geschleppt haben, da ich kurz vor Cuxhaven gegen den Strom stand, nach 16 Stunden an der Pinne komplett übermüdet. Ich hatte mich selbst kronisch überschätzt. Einhand und ohne davor Seeerfahrung auf die Nordsee? Geht. Aber Babysteps - und nicht gleich einen weiten Schlag unternehmen. Das andere war wohl meine Beinahe-Strandung vor Neuwerk. Es stand eine ordentliche Welle in der Flachen Hafenausfahrt. Mein Bauch sagte mir ganz klar: Nicht rausfahren! Aber mein Kopf hat beschlossen den Zahlen zu vertrauen, die dafür geprochen haben das es klappen sollte. Man ist selbst vor Ort. Natürlich sollte man die Entscheidung nicht nur vom Bauchgefühl abhängig machen. Aber wenn der Bauch schon sagt das etwas eine Scheißidee ist - dann hat das meistens seine Berechtigung. Dieser Selbstbetrug hätte mich auch mein Boot kosten können - erst im letzten Monat kam ich von untiefe neben dem Hafen runter und zurück ins Hafen. Ich war im wahrsten Sinne des Wortes nur noch wenige Meter von der Hafeneinfahrt entfernt. Was empfiehlst Du jemandem, der mit dem Segeln beginnen oder sich weiter entwickeln möchte? Machen! Unbedingt machen. Natürlich kann man erst lange Kurse machen, theoretisieren... Aber am Ende lernt man auf See. Und der Schein mit der mit Abstand steilsten Lernkurve ist der Kaufvertrag des ersten seegehenden Bootes. Aber: Langsam, mit Bedacht. Sprich, nicht als ersten Seeschlag einhand von Hooksiel nach Cuxhaven. Sondern kleine Schläge oder Schläge, bei denen es viele Möglichkeiten gibt kurzfristig den Tag auf dem Wasser zu beenden. Gut geeignet dafür sind zum Beispiel die Niederländischen Binnenreviere. Aber es geht auch auf der Nordsee. Eben da, wo man künftig segeln will.    Welchen „letzten Tipp“ kannst Du uns und unseren Zuhörern mit auf dem Weg geben? Vergesst "so groß wie möglich". Den Tipp findet man hundertfach im Internet und hört ihn auch in Gesprächen immer wieder. Ich glaube ehr an "So klein wie möglich, so groß wie nötig". Natürlich kann man das Boot im Nachhinein nicht vergrößern. Aber eben auch nicht verkleinern. Jeden Fuß, den so ein Boot länger wird, wachsen nicht nur die Kosten sondern auch der Anschaffungspreis. Bereits ein vergleichsweise kleines 22 Fuß Boot wie meines kann sehr seegängig und zugleich wohnlich sein. Wem dies, so wie mir reich, der sollte sich nicht einreden lassen er bräuchte dreißig oder gar vierzig Fuß. Ein weiterer Vorteil: Man kann es sich früher leisten - und somit früher seinen Traum leben. Ich plädiere ganz klar dafür, as Leben so weit wie möglich zu vereinfachen um jetzt glücklich zu sein, statt in einer viel zu oft fernen und ungewissen Zukunft. Wie kann man Dich erreichen, wenn man Fragen an Dich hat oder mit Dir in Kontakt kommen möchte? Am besten über meinen Blog www.segeln-ist-leben.de oder meine Facebookseite. [newsletter]  

www.segelpodcast.com 047 - Live SKS Törn vor Mallorca Teil 1 In der Folge 047 - Live SKS Törn vor Mallorca Teil 1 berichte ich dir live aus Mallorca was ich mit meiner 6 köpfigen Crew während des SKS Ausbildungstörns alles unternommen haben. 047 - Live SKS Törn vor Mallorca Teil 1 - Los geht´s Ich grüße dich heute aus Mallorca. Ich bin in der Marina von El Arenal und da mache ich einen SKS Ausbildugnstörn, bei dem ich die Skipperin bin und ich werde dich jetzt mitnehmen auf diesen Törn und immer mal wieder zwischendurch, wenn ich dran denke, etwas sagen wie das hier abgeht bei diesem Törn. Boarding In diesem Fall war das so gewesen, dass die Crew am Samstag um 16 Uhr an Bord gekommen ist. Also nicht tröpfchenweise, das habe ich auch schon erlebt, sondern wirklich um 16 Uhr sollten die alle da sein. Es hat dann doch ein bisschen länger gedauert bis alle da waren, weil zwei hatten einen späteren Flug, die hatten den ersten verpasst und haben dann einen neuen Flug gebucht und sind dann etwas später gekommen. Nach der ersten Begrüßung und dem ersten kennen lernen ist es dann erst mal so, dass man einkaufen geht. Und das haben wir dann so gemacht. Wir haben erst mal besprochen was noch an Bord ist und was noch benötigt wird. Dazu gibt es eine Essensliste, die wir dann durchgegangen sind. Dann haben wir besprochen ob wir Essen gehen möchten oder ob wir lieber an Bord kochen in dieser Woche und dann haben die, die kochen möchten ihre Wünsche geäußert, was sie brauchen. Und dann sind zwei Mann zum Mercadona gelaufen, der hier in 10 Min. fußläufig zu erreichen ist. Und haben dann drei Wägelchen voll gemacht. Vor allem mit Getränken. Das macht Sinn Getränke da einzukaufen wo man die Möglichkeit dazu hat und nicht schleppen muss. Und dann sind die mit dem Taxi hier her gefahren und wir haben alle zusammen die Einkäufe ausgeladen. Während die zwei einkaufen waren hatten die anderen frei. Dann haben wir die ganzen Sachen verstaut. Derweil sind auch unsere Nachzügler gekommen und dann waren wir komplett und gingen Essen. Aus Einfachheitsgründen haben wir dann nicht an Bord gekocht, da hatte auch keine mehr Lust zu. Am Anreisetag ist man ja immer ein bisschen erledigt und fertig und dann waren wir im Marinarestaurant. Und beim Essen haben wir uns gegenseitig ein bisschen vorgestellt und hatten eine angenehme Zeit da. Wir konnten uns ein bisschen beschnuppern. Die Crew die ich hier hab, ist klasse. Sehr nette Leute. Ein Ehepaar, Papa und Sohn und zwei Freunde, die sich schon ewig kennen und ihre Familien einmal zu Hause gelassen haben. Ja, und dann sind wir wieder an Bord gegangen und ich habe denen noch erzählt wie die Toilette funktioniert und das Gas. Also alles vorbereitet, dass wir morgen früh auch frühstücken können. Wobei, wenn wir Landstrom haben können wir auch mit dem Wasserkocher Wasser für den Kaffee heiß machen. Neuer Tag mit viel Input Und dann war klar: Um 8 Uhr wird aufgestanden, um 9 gibt es Frühstück und um 10 Uhr fängt dann die nächste Sache an die dann kommt, was in unserem Fall, jetzt heute die Sicherheitseinweisung war. Ich habe dann alles Wichtige eben mit der Crew besprochen. Inzwischen haben wir 13 Uhr. Das war sehr ausführlich, sehr intensiv. Über Sicherheitseinweisung habe ich eine extra Folge gemacht: http://segelpodcast.com/020-crew-und-sicherheitseinweisung. Und dann habe ich denen alles erklärt was an Bord wichtig ist. Es ist ja ein SKS Törn, es sind aber nur zwei dabei, die auch geprüft werden. Das wird am Freitag sein. Also Samstag ist Ankunftstag, dann wird die Woche über trainiert, Freitag ist Prüfung und am Samstag um 8 Uhr darf die Crew wieder von Bord gehen. Und wird dann wohl super viel gelernt haben. Und zwei sind dann ja auch dabei, die wahrscheinlich ihre praktische SKS Prüfung bestanden haben. Und jetzt nach der Sicherheitseinweisung haben wir noch eine kleine Pause, da bereiten jetzt noch ein paar was zu, damit wir noch ein bisschen Essen in den Bauch bekommen und dann geht es raus auf´s Wasser und wie es dann weiter geht, das erzähl ich dir dann, wenn ich noch mal Zeit dazu finde. Bis dahin Tschüssjen Hallo hier bin ich wieder. Es ist jetzt Sonntag Abend. Wir liegen in einer wunderschönen Bucht (bei Illetas) in der Bahia de Palma vor Anker. Wir haben heute super viel gemacht. Ich habe ja 6 Schüler bei diesem SKS Törn, aber nur zwei werden am Ende die Prüfung machen am Freitag. Die anderen 4 wollen lernen. Und die haben heute mal das Schiff kennen gelernt, wenn es unter Motor fährt, wenn man nach Kurs fährt. Also da habe ich dann gesagt: Fahr mal 180°, fahr mal 240°. Und dann haben sie mal das Schiff kennen gelernt was das Ruder betrifft. Wie man es steuert. Dann haben wir ein bisschen die Schaltung kennen gelernt. Es gibt ja nur Vorwärtsgang, Leerlauf und Rückwärtsgang und da haben wir dann Vorausfahrt gemacht mit der Fahrtgeschwindigkeit von max. 1800 Umdrehungen oder ein bisschen weniger. Und dann Aufstoppen. Vom Leerlauf in den Rückwärtsgang hinein und dann mit einem kurzen Pusch im Rückwärtsgang einigermaßen zum stehen zu kommen. ... www.segelpodcast.com

Special Guests: John Landstrom, owner of Blue Moon Cycle Ask anyone in the south about the highest quality antique motorcycle shop, and Blue Moon Cycle is bound to be at the top of that list. Since 1987, Blue Moon Cycle has maintained as an icon in the Atlanta, Georgia motorcycle scene. Over the years, Blue Moon’s day-to-day operations revolved around the sales and service of modern BMW motorcycles. Owner John Landstrom prides himself on having operating one of the smoothest-running BMW motorcycle franchises in the country, and the determination of his highly skilled staff to go the extra mile to ensure customer satisfaction. In addition to selling late model machines, Blue Moon is well known as a parts distributor for antique European motorcycles dating back to the 1950s.  Most recently, John made the decision to sell his BMW dealership franchise and focus on strictly vintage motorcycles. On September 12th, 2015, Blue Moon Cycle officially re-opened to welcome its visitors to a showroom and museum where more than 100 vintage European machines are on display. Dozens of beautiful BMW, DKW, Horex, NSU, and Adler motorcycles are presented, as well as rare makes and models such as Bohmerland, Munch, Immer and Gnome Rhone. In addition to the collection of motorcycles available on display, John Landstrom is well known for his adventures with rare and exotic motorcycles around the globe. This week on Classic Chrome, we are excited to be joined by Mr. John Landstrom himself, who will be sitting down for an exciting hour of his motorcycle tales and more information about the Blue Moon Cycle collection. Blue Moon Cycle Website: www.bluemooncycle.com

Special Guests: John Landstrom, owner of Blue Moon Cycle Ask anyone in the south about the highest quality antique motorcycle shop, and Blue Moon Cycle is bound to be at the top of that list. Since 1987, Blue Moon Cycle has maintained as an icon in the Atlanta, Georgia motorcycle scene. Over the years, Blue Moon’s day-to-day operations revolved around the sales and service of modern BMW motorcycles. Owner John Landstrom prides himself on having operating one of the smoothest-running BMW motorcycle franchises in the country, and the determination of his highly skilled staff to go the extra mile to ensure customer satisfaction. In addition to selling late model machines, Blue Moon is well known as a parts distributor for antique European motorcycles dating back to the 1950s.  Most recently, John made the decision to sell his BMW dealership franchise and focus on strictly vintage motorcycles. On September 12th, 2015, Blue Moon Cycle officially re-opened to welcome its visitors to a showroom and museum where more than 100 vintage European machines are on display. Dozens of beautiful BMW, DKW, Horex, NSU, and Adler motorcycles are presented, as well as rare makes and models such as Bohmerland, Munch, Immer and Gnome Rhone. In addition to the collection of motorcycles available on display, John Landstrom is well known for his adventures with rare and exotic motorcycles around the globe. This week on Classic Chrome, we are excited to be joined by Mr. John Landstrom himself, who will be sitting down for an exciting hour of his motorcycle tales and more information about the Blue Moon Cycle collection. Blue Moon Cycle Website: www.bluemooncycle.com

Kaum ein Thema polarisiert in der öffentlichen Diskussion um die Kreuzfahrt so sehr wie der Aspekt Umweltschutz. Die einen sehen Kreuzfahrtschiffe als üble Dreckschleudern, die anderen kritisieren die aus ihrer Sicht einseitige Betrachtung des Themas bei Umweltschutzverbänden und in den Medien. In dieser Folge des cruisetricks.de Kreuzfahrt-Podcasts nehmen uns der Frage an, was die Kreuzfahrt insbesondere für die Luftreinhaltung tut, was sie tun könnte aber nicht tut und welche Aspekte bei diesem Thema eine wichtige Rolle spielen – nicht jedoch ohne zuvor ein leidenschaftliche Plädoyer für eine sachlichere, Fakten-orientierte Diskussion zum Thema Abgase und Umweltschutz in der Kreuzfahrt zu halten. Die Podcast-Folge thematisiert Aspekte wie Reduzierung des Energieverbrauchs zur Senkung des CO2-Ausstoßes, Abgasfilter und auf welchen Schiffen sie zum Einsatz kommen, diskutiert alternative Treibstoff zum gängigen Schweröl, geht auf Landstrom und Stromversorgung über LNG-betriebene Power-Barges ein und versucht einen Blick in die Zukunft. Bewusst klammern wir andere Umweltschutzaspekte in der Kreuzfahrt in dieser Folge aus, beispielsweise Müllentsorgung und Nachhaltigkeit beim Bau und Betrieb der Schiffe. Das Thema heben wir uns für eine separate Folge auf, weil es zu wichtig ist, um neben dem dominanten Abgas-Thema unterzugehen …

Podcast zur Landstromversorgung von Schiffen und den gefährlichen Treibstoffen. Schiffe spielen besonders in Hamburg eine große Rolle, der Hafen dominiert die Stadt und macht sie aus. Aber es gibt nicht nur den romantischen Blick auf den Hafen und die Schiffe, sondern auch eine Kehrseite des ganzen. Schiffe stoßen durch die Verbrennung von Treibstoff viele gifte und ungesunde Stoffe aus. Eine Alternative und Möglichkeit die Luftqualität in Häfen besser zu machen ist Landstrom. Was das genau ist erklärt Jörg Feddern.